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Abstract 
Cellular division is primarily controlled at the G1 to S-phase transition of the cell cycle by 
the retinoblastoma tumor-suppressor protein (pRB). The ability of pRB to restrict S-phase 
entry is primarily attributed to the repression of E2F transcription factors required to 
upregulate cell cycle target genes necessary for cellular division. Interestingly, while pRB is 
disrupted in the vast majority of human cancers, mutations typically target upstream 
regulators of pRB leading to inactivation through hyperphosphorylation. The rarity of direct 
pRB mutations suggests that the regulation of the cell cycle by pRB may involve additional 
mechanisms outside of E2F repression, as this could to be eliminated via point mutations. 
Indeed, the Rb1G/G mouse model developed by Cecchini et al., which lacks the ability to form 
pRB-E2F complexes, showed minimal phenotypic alterations. As described in chapter 2, 
pRB can stabilize p27 in the absence of pRB-E2F interaction, maintaining cell cycle control. 
Importantly, the loss of pRB-E2F interactions in addition to the loss of p27 leads to a 
defective DNA damage response, and ultimately pituitary tumor development. The minimal 
region of pRB necessary to elicit a cell cycle arrest is the pRB large pocket which contains 3 
distinct binding surfaces. Using synthetic mutants of pRB we show that all three of these 
sites play a role in regulating the cell cycle both in vitro and in vivo. Finally, to understand 
E2F independent pRB-mediated tumor-suppression, Rb1G/G mice were intercrossed with 
mice harboring oncogenic KrasG12D, or deletions of p21 or p53. While KrasG12D expression-
induced tumorigenesis was not further affected by the Rb1G mutation, the phenotype of p53 
null animals was exacerbated by the Rb1G mutation. Interestingly, the loss of p21 in Rb1G/G 
mice showed no tumor development despite the overlapping function with p27. While it is 
unclear why there is a discrepancy in phenotype between Rb1G/G mice lacking p21 and those 
lacking p27, p27 has non-canonical functions which may be contributing to tumor 
development. Taken together this work describes E2F independent functions of pRB in cell 
cycle control and tumor suppression and provides a rationale for the unusual disruption of 
pRB in human cancers by hyperphosphorylation. 
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Chapter 1  
1 Introduction 
1.1 Overview 
Cancer can be characterized as an overall loss of homeostasis in a multicellular 
organism resulting in aberrant growth and the development of a tumor1. Over the years, 
several pathways have been described as playing critical roles in carcinogenesis1. Several 
factors work together to bring about this phenotype, ranging from the ability to proliferate 
independent of growth signals, to bypassing fail-safe mechanisms designed to inhibit cell 
growth or initiate programmed cell death in response to aberrant cell growth1. Therefore, 
the mechanisms that are involved in regulating cell cycle control are often targets of 
cancer causing mutations1. Once mutations arise in these critical pathways the affected 
cell is then capable of bypassing the various tumor suppressive functions and divide 
uncontrollably resulting in tumor formation. As such, cellular proliferation is a key 
component of cancer development and progression. Understanding the mechanisms that 
control proliferation is critical to the development of novel targeted therapies that aim to 
re-establish proliferative control in cancer cells. 
1.2 Cellular division 
The process through which cells proliferate is known as the cell division cycle2. The 
cycle is split into 4 main phases separated by 3 checkpoints to regulate the transitions 
between them (Figure 1.1)3,4. Cellular division is tightly regulated in the body to ensure 
that various tissues are sustained at appropriate sizes, and vital structures are maintained5.  
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Figure 1.1: Depiction of the mammalian cell cycle. 
The 4 phases of the cell cycle are indicated: Gap 1 (G1), Synthesis (S), Gap 2 (G2), and 
Mitosis (M). Also indicated are the 3 main checkpoints that regulate cell cycle 
progression at various stages. The restriction point controls the transition between G1 and 
S-phase ensuring appropriate proliferation. The DNA damage checkpoint occurs in G2 
and ensures the DNA is intact prior to Mitosis. Finally, the spindle assemble checkpoint 
confirms that each chromosome pair is attached to both spindle poles prior to cytokinesis. 
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As such, several pathways including but not limited to, growth factors, cell to cell 
contacts and mitogen availability are all important to controlling cellular division6-8. Due 
to the critical involvement of cellular proliferation in carcinogenesis all cancer cells must 
bypass these growth regulatory pathways1,6,8. While normal cells without appropriate 
signals will not enter the cell cycle, the acquisition of mutations in critical tumor-
suppressive or oncogenic pathways can lead to the re-entry of these cells into the cell 
cycle and potentially lead to tumor development1,9.  
Given the possibility of cancer developing due to a defective cell division cycle, 
cellular proliferation is tightly controlled to ensure that 2 daughter cells are faithfully 
produced and only when it is appropriate to do so. For actively cycling normal cells, the 
first phase of the cell cycle known as Gap 1 phase (G1) in which the cell, through a series 
of growth signalling pathways, determines if conditions are appropriate to initiate cell 
cycle progression10,11. Additionally, in this phase the cell physically grows and produces 
a variety of proteins that are needed for DNA replication12. Once appropriate conditions 
are met for cell cycle entry, the cell then transitions into the synthesis-phase also known 
as S-phase in which DNA is replicated13. To ensure that the DNA is only replicated once 
per division it is critical that once a cell has begun to replicate its DNA that the cell cycle 
is completed and cells do not revert to an earlier phase14-16. Therefore, given the 
importance of the G1-S transition phase boundary, it is understandable that this transition 
is tightly regulated and known as the restriction point and the first major checkpoint in 
the eukaryotic cell cycle (Figure 1.1)15,16. 
In late G1 phase, a variety of proteins which are needed for DNA replication are 
transcribed and translated17. These include a number of kinases, transcription factors, as 
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well as replication fork components17. The prereplication complexes are then loaded on 
the chromatin at origins of replications18. Following activation by S-phase kinases these 
proteins can then unwind the DNA and begin the process of replicating the genome18. 
Since prereplication complexes can only be loaded in G1 this ensures that DNA is only 
copied once per cell cycle18. Once the genome is fully replicated, the cell is then said to 
be in the Gap 2 phase of the cell cycle or G2. Again, in this phase more proteins and 
lipids are made in preparation for mitosis. In addition, the G2 phase of the cell cycle also 
contains a DNA damage checkpoint in which the cell ensures that the genome is intact 
and fully replicated prior to entry into mitosis (Figure 1.1)19. 
During the fourth phase of cell division, mitosis (M-phase), the genome condenses 
greatly, the nuclear envelop disintegrates, and the duplicated sister chromatids are aligned 
in the center of the cell at the metaphase plate20. The final checkpoint of the cell cycle 
then ensures that each pair of sister chromatids are bound by a spindle emanating from 
the centrioles on either side of the cell21. Once this is confirmed the sister chromatids are 
separated and one set is pulled towards each pole located at the periphery of the cell21. 
The cell then pinches in the middle leading to cleavage and the creation of two daughter 
cells in the G1 phase of the cell cycle through a process known as cytokinesis22. While 
there are 3 main checkpoints in the cell cycle, the G1 restriction point is unique in the 
ability to determine whether the cell divides or not12,14,19,21. The remaining two 
checkpoints, the G2 DNA damage checkpoint and the spindle assembly checkpoint, are 
only able to stall the cell cycle and once the problems are corrected the cell then resumes 
the cell division cycle (Figure 1.1)19,21.  
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As the G1 to S-phase transition is unique in its ability to determine if the cell will 
divide or remain quiescent, the pathways involved in this transition are highly 
regulated8,14. Moreover, with the importance of this restriction point in regulating the 
proliferation of cells it is often targeted by mutation in human cancers1. There are several 
proteins which help to regulate this critical restriction point of the cell cycle8,10. These 
proteins translate intra- and intercellular signals that ultimately influence the activity of 
two protein families which work in opposition to one another23. The branch which 
promotes cell cycle entry is a group of kinases known as Cyclin dependent kinases 
(CDKs)23. In contrast, a second group known as Cyclin dependent kinase inhibitors 
(CKIs) works to prevent cell cycle advancement through direct interaction with CDKs, 
inhibiting their activity23. Ultimately, these two sets of proteins determine the activity of 
one of the key regulators of the G1-S transition, the retinoblastoma tumor suppressor 
protein (pRB)24. The interactions between CDKs, CKIs, and pRB and how they influence 
one another in the context of cell cycle control is the focus of this thesis.  
1.3 Identification of the retinoblastoma susceptibility 
gene 
The retinoblastoma tumor suppressor gene was first predicted through the study of the 
childhood eye cancer, retinoblastoma25. Retinoblastoma presents in two different forms, 
either unilateral, occurring in one eye, or bilateral, occurring in both eyes25. In 1971, 
Alfred Knudsen discovered that those children developing bilateral retinoblastoma 
typically had a family history of the disease25. These children also developed cancer far 
earlier than those developing unilateral cancer, which occurred later and typically had no 
family history of retinoblastoma25. From this study Knudsen suggested his 2 hit 
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hypothesis, which states that the development of retinoblastoma requires the loss or 
mutation of both copies of a retinoblastoma susceptibility gene25. This description of the 
retinoblastoma susceptibility gene is the first example of a tumor suppressor protein, 
which has since gone on to describe several proteins involved in the maintenance of 
cellular homeostasis and the prevention of tumorigenesis. 
1.4 Cloning of the RB1 gene. 
The susceptibility factor associated with retinoblastoma development predicted by 
Knudsen in 1971 was eventually found to be contained within a region on the q arm of 
chromosome 1326. In 1986 two independent groups cloned this retinoblastoma 
susceptibility gene referred to as the retinoblastoma gene (RB1)27,28. Consistent with 
Knudsen’s hypothesis, patients with heritable forms of retinoblastoma were found to have 
mutations in one copy of this gene throughout their body29. A second genetic event then 
occurs somatically in the retina leading to the development of retinoblastoma in children. 
This confirmed Knudsen’s two hit hypothesis and identified the first tumor suppressor 
gene.  
This disruption of the RB1 gene while critical for the development of retinoblastoma 
started to be seen in other cancers26,30,31. First, those patients who survive retinoblastoma 
as children have a likelihood of developing osteosarcoma far greater than that of the 
general population26. Furthermore, these cancers also displayed the loss of heterozygosity 
(LOH) or loss of the wild-type allele of the RB1 gene similar to the development of 
retinoblastoma26. Additionally, direct RB1 mutation has also been identified in a large 
majority of small cell lung cancers (SCLC) and a sizable proportion of breast cancers30,31. 
However, typically mutations in the pRB pathway occur upstream of pRB resulting in the 
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hyperphosphorylation of pRB leading to its functional inactivation30. Two of the most 
common pathway mutations are deletion of p16 or amplification of Cyclin D both of 
which lead to constitutive pRB hyperphosphorylation, inhibiting its various functions30 
The repercussions of functional disruption of pRB will be discussed later on. The 
prevalence of pRB pathway disruption through direct or indirect mutation in cancers from 
various disease sites suggests that the retinoblastoma gene product (pRB) encoded by the 
RB1 gene is important in some vital cellular process which cells must bypass to become 
tumorigenic. 
1.5 pRB and viral oncoproteins 
Shortly after cloning the RB1 gene, pRB was shown to directly interact with a variety 
of viral oncoproteins including HPV-E7, SV-40 Large T antigen and Adenovirus E1A32-
34. As their name suggests, these viral oncoproteins can transform cells leading to 
tumorigenesis35. Unsurprisingly then, when expressed these viral oncoproteins cause cells 
to re-enter the cell cycle regardless of the presence or absence of growth factors35. 
Importantly, the association between pRB and viral oncoproteins leads to a disruption of 
pRB function either through the degradation or sequestration of pRB molecules36. Given 
the importance of pRB in tumor suppression both in retinoblastoma as well as a large 
variety of other cancers, and the fact that disruption of pRB function by viral 
oncoproteins is coincident with cellular proliferation, it was suggested that pRB had a 
role in the regulation of cell cycle progression32-35 Finally, this role is likely ubiquitous as 
the regulation of the cell cycle is important in all cells and not just the tumor cells in 
which they are mutated. 
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1.6 pRB-family proteins 
The pRB family of proteins which consists of pRB, p107, and p130, are collectively 
known as the pocket proteins as they all contain the characteristic pocket domain37-39. 
Furthermore, these were all identified through their ability to interact with the viral 
oncoproteins E1A, E7 and SV-40 T antegin39-41. The characteristic pocket domain is 
formed from two cyclin folds in the A and B domains of these proteins and facilitates the 
association between the pocket protein and the E2 promoter binding factor (E2F) 
transcription factors (Figure 1.2)42. While all three proteins contain this structure, p107 
and p130 are more similar to each other in terms of sequence and have slightly different 
pocket domains compared to pRB37. In particular, p107 and p130 contain an insertion 
into the B domain of the pocket which may have implications in regulating their specific 
binding partners (Figure 1.2)37. Pocket proteins lack DNA binding ability and therefore 
must be recruited onto DNA by the various E2Fs with which they associate43. This means 
that chromatin localization relies not on the pocket protein itself but rather the consensus 
sequence of the E2F transcription factors. Furthermore, in addition to binding to E2F 
transcription factors, pocket proteins can also act as a scaffold to bring much larger 
complexes to specific locations on the DNA which can further repress transcription44. 
1.7 Regulation of pocket proteins 
The ability of the pocket proteins to influence E2F transcription factors is regulated 
by two independent factors, expression and phosphorylation status. In general, the 
expression of p107 and p130 fluctuate throughout the cell cycle with p130 being 
expressed at high levels in quiescence, or G0 of the cell cycle and diminishing as the cell 
progresses through G1 and S37. p107 by contrast, is most highly expressed in S-phase as  
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Figure 1.2: Domain structure and interaction surfaces of pocket proteins. 
(A) The A, B, and the C-terminal domains are shown for all 3 pocket proteins. The large 
pocket is denoted by the red line and the small pocket is identified by the green line. (B) 
The three large pocket interaction sites in pRB are shown. These are the E2F general 
interaction facilitated by the entire large pocket, the LxCxE binding cleft located in the B 
region of the pocket and the E2F1 specific interaction site which associates with pRB 
through an interaction site in the C-terminus. 
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it is a target of E2F dependent transcription37. pRB, on the other hand remains relatively 
stable throughout the cell cycle with a slight increase in expression in S-phase due to E2F 
dependent transcription37. The relative stability of pRB expression throughout the cell 
cycle indicates that control of its function is largely independent of transcription and is 
controlled instead by post-translational modifications, in particular phosphorylation45. 
Phosphorylation of pRB as well as the other pocket proteins is largely carried out by 
Cyclin/CDK complexes45,46. Once a cell is stimulated to divide there is an increase in the 
activity of Cyclin/CDK complexes leading to the phosphorylation of pRB disrupting 
various interactions due to conformational changes45,46. 
1.8 Structure of pRB 
The retinoblastoma gene product (pRB) is a globular protein which contains several 
interacting domains which together regulate numerous cellular proteins influencing the 
cell cycle45,47. The majority of these characterized domains are located in the C-terminal 
two thirds of the protein which is referred to as the large pocket (Figure 1.2A)47. The 
large pocket itself is made up of 3 main structures, the A and B domains each comprise of 
cyclin folds which are joined together with a spacer creating the small pocket (Figure 
1.2A)42. The large pocket is made up of this small pocket and the unstructured C-terminal 
domain47. This thesis focuses on three independent binding interactions located in the 
large pocket of pRB. These interactions are known as the general E2F binding site, the 
LxCxE binding cleft and the E2F1 specific binding site (Figure 1.2B)42,45,48. 
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1.9 pRB-E2F interactions 
First, and most well known of the various pRB interactors are the E2F transcription 
factors43. This interaction is facilitated through the pocket domain of pRB and is involved 
in pRB-mediated regulation of the cell cycle43. The importance of pRB-E2F regulation in 
the cell cycle was initially identified through the use of Saos-2 arrest assays49,50. In these 
early experiments, it was shown that the minimal interacting domain necessary for pRB-
E2F association was also able to initiate a cell cycle arrest when expressed in Saos-2 
cells49,50. Given this correlation, it is logical to assume that pRB-E2F interaction is 
critical to regulation of the restriction point49,50. However, as shown in Figure 1.2, the 
minimal domain required for pRB-E2F interaction, the large pocket, also contains a least 
two other binding surfaces, the LxCxE binding cleft and the C-terminal E2F1 specific 
interaction site (Figure 1.2B)42,50,51. This suggests that the ability of pRB to regulate the 
cell cycle may be dependent on several interactions not just pRB binding to E2Fs. 
1.10 Disruption of pRB by viral oncoproteins 
Of particular note both viral oncoproteins, HPV-E7 and Adenovirus E1A have 
multiple domains that are required for the effective association and inactivation of pRB 
as well as their ability to transform cells52,53. HPV-E7 eliminates pRB function by 
targeting the protein for degradation53. As such, HPV-E7 requires both the CR2 domain 
which contains the LxCxE motif to associate with pRB, as well as the CR1 domain which 
recruits additional factors targeting the protein for degradation35,53. Additionally, the C-
terminus of HPV-E7 contains a low affinity pRB binding domain which is thought to 
interact with the pRB-E2F binding pocket preventing E2F binding35. By contrast, E1A 
eliminates pRB function through sequestration of pRB preventing it from functioning 
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properly53. E1A contains two binding domains that are essential to oncogenic 
transformation52. The CR1 domain mimics the transactivation domain of E2F and binds 
in the pocket of pRB, this however is not sufficient to transform cells52. The CR2 domain 
of E1A contains the LxCxE domain which also allows for association between pRB and 
E1A, however, once again this is not sufficient to allow for oncogenic transformation52. 
The requirement for disruption of both the pocket domain and the LxCxE binding domain 
to successfully sequester pRB was some of the first evidence that pRB-E2F interactions 
are not solely responsible for the tumor suppressive abilities of pRB. Presented in this 
thesis are experiments which attempt to further explore the various functions of pRB 
outside of the dogma of pRB repressing E2F dependent transcription. 
1.11 E2F transcription factors as regulators of the cell 
cycle 
The E2F proteins are a family of transcription factors which bind to a variety of target 
gene promoters to influence transcription necessary for regulating cell cycle entry54. This 
family can be further divided into transcriptional activators (E2F1-3) and transcriptional 
repressors (E2F4-5)54. Finally, there are three atypical E2Fs, (E2F6-8) whose function is 
currently being explored, but are generally thought to be repressive and function 
independently of pocket proteins55. Together with their dimerization partner, 
Differentiation related transcription factor-1 polypeptide-1 (DP1) the activator E2Fs form 
a heterodimer which binds to promoters of genes involved in DNA synthesis and cell 
cycle progression54. Critically, activator E2Fs (E2F1-3) have been shown to be necessary 
to allow for cellular division56. This function of E2F transcription factors is facilitated 
through the transactivation domain located in the C-terminus of the activator E2Fs54. This 
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domain is responsible for recruiting transcriptional co-activators such as p300 leading to 
the upregulation of genes important for S-phase progression43. Importantly, in cells 
stimulated to enter the cell cycle, E2F target genes are greatly upregulated coincident 
with S-phase entry and DNA synthesis43. To prevent aberrant cell cycle entry, pRB 
regulates E2F-mediated transcription through the pRB pocket domain45. pRB is unique 
among pocket proteins for its ability to bind to activator E2Fs (E2F1-3), in addition to the 
repressor E2F443,57. By contrast p107 and p130 both only associate with the repressive 
E2Fs (E2F4-5)43. This pocket formed between the A and B domains in pRB creates a 
docking site which binds to the transactivation domain of E2F1-445. This interaction 
precludes any recruitment of co-activators by E2Fs preventing the upregulation of genes 
that are necessary to drive the cell into S-phase (Figure 1.3)58. Finally, by high jacking 
E2F DNA binding ability, pRB can act as a scaffold recruiting a variety of chromatin 
remodeling factors which can further condense chromatin and prevent the transcription of 
E2F targets (Figure 1.3)46,59,60. 
1.12 Additional RB binding sites 
The characteristic pocket domain of pRB is created through the folding together of 
the two cyclin folds in the small pocket of pRB known as the A and B domain (Figure 
1.2)45. In addition to contributing to the small pocket binding domain, the B-domain of 
pRB also contains a protein interacting region known as the LxCxE binding cleft47. This 
surface is so named as viral oncoprotein binding to pRB is mediated through the LxCxE 
peptide sequence present on these viral oncoproteins61. In addition to being a binding site 
for viral oncoproteins that inactivate pRB, several cellular proteins have now been  
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Figure 1.3: Regulation of the G1 to S-phase transition by pRB. 
In G1 hypophosphorylated pRB binds to E2F/DP heterodimers masking their ability to 
stimulate the transcription of genes including but not limited to Mcm3, Rbl1, and, Ccne1, 
which are required for cell cycle entry. Additionally, pRB can recruit chromatin 
regulatory factors (CRFs) through its LxCxE binding cleft, which compact the DNA at 
these genes further repressing transcription. Once the cell is stimulated to divide an 
increase in Cyclin/CDK activity, particularly Cyclin E/CDK2 and Cyclin D/CDK4/6, 
results in the hyperphosphorylation of pRB. These phosphorylation events lead to large 
scale conformational changes to the pRB protein resulting in the disruption of both 
E2F/DP interactions and interactions with LxCxE interactors including Chromatin 
regulatory factors. E2F/DP heterodimers are then capable of stimulating S-phase required 
genes promoting cell cycle entry.  
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suggested to interact with pRB through the LxCxE binding cleft47,62. Some of these 
proteins include a variety of chromatin remodelers such as HDACs, and Condensin II, 
which influence the accessibility of chromatin to transcriptional machinery44,60,61,63. 
Interestingly, as pRB contains no known DNA binding activity, pRB is carried to E2F 
target genes essentially changing the E2F-DP transcription factor from a transcriptional 
activator into a repressive complex43. This is accomplished both by the masking of the 
transactivation domain on E2F as well as the recruitment of chromatin remodelers which 
further compact chromatin preventing transcription specifically at genes regulated by 
E2Fs. Finally, a third binding site exists in the C-terminus of pRB which has been less 
well characterized as the other two, through which E2F1 can bind to pRB in a unique 
conformation51. This interaction has recently been established as a method through which 
pRB can inhibit the expression of repeat elements in the genome, such as endogenous 
retroviruses60. 
The combined action of pRB direct inhibition of the transactivation domain of E2Fs 
and the recruitment of chromatin remodelers together comprise a model of cell cycle 
restriction and tumor suppression through the which pRB inhibits the expression of genes 
required for S-phase progression (Figure 1.3). However recent findings have presented 
doubt on this dogma. As an example, the development of mutations which target pRB 
transcriptional regulation have relatively minimal effects on the cell cycle regulatory 
functions of pRB48,64,65. In this thesis, I explore the importance of the transcriptional 
independent functions of pRB and present evidence which disputes this linear view of 
pRB function at the G1 to S transition (Figure 1.3). 
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1.13 Regulation of pRB activity by CDK 
phosphorylation 
Expression of pRB is relatively stable throughout the cell cycle and in fact increases 
as the cell progresses through S-phase37. This increase is a result of an increase in E2F 
activity as the RB1 gene is upregulated by E2F transcription factors66. Given that pRB is 
an inhibitor of S-phase entry, increasing expression of RB1 during this transition implies 
that the regulation of the RB protein is controlled not through transcription. In addition to 
the increased protein levels as the cell progresses through G1 and into S-phase, pRB 
becomes hyperphosphorylated (Figure 1.3)67. pRB contains no less than 13 CDK 
phosphorylation sites which are located throughout the protein, primarily in intrinsically 
disordered regions45. These sites are targeted by Cyclin D/CDK4/6 complexes as well as 
Cyclin A/E /CDK2 complexes67. Importantly, Cyclin/CDK complexes are the main 
proteins responsible for driving the cell cycle, further supporting the role of pRB as a 
repressor of cell cycle progression68.  
Once activated, the Cyclin/CDK phosphorylation of pRB results in the compaction of 
the pRB protein in such a way that it no longer has open binding surfaces in the large 
pocket (Figure 1.4)45. The pRB N-terminus and the pocket domain fold together due to 
phosphorylation at T373 (Figure 1.4)45. The linker present in the B-Box becomes 
phosphorylated at S608 and S612, and sits in the E2F binding site, and the pRB C-
terminus is phosphorylated at residues T821 and T826 causing folding into the LxCxE 
binding cleft (Figure 1.4)45. The result of these phosphorylation events is the disruption 
of both the pRB-E2F general interaction and the LxCxE binding cleft (Figure 1.4)45.  
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Figure 1.4: Compaction of pRB following phosphorylation. 
When pRB is hypophosphorylated in the G1 phase of the cell cycle all three of the 
interaction surfaces in the pRB large pocket, the E2F general site, LxCxE binding cleft 
and the E2F1 specific site are free to bind their ligands. In S-phase, pRB is 
hyperphosphorylated leading to compaction of the pRB molecule through the interaction 
of the pRB N-terminal domain (RBN) binding to the Pocket domain controlled by 
phosphorylation at T373. Furthermore, E2F general interactions and the LxCxE 
interactions are disrupted through phosphorylation and docking of the pocket loop (S608, 
S612) and pRB C-terminal domain (RBC) (T821, T826) respectively. Yellow circles 
denote phosphorylation events. 
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Importantly, this compaction of the pRB protein suggests that both the LxCxE binding 
cleft and pocket domain are important for cell cycle control. However, classical models 
of pRB cell cycle restriction suggest that the LxCxE binding cleft is responsible for 
compacting chromatin around E2F target genes preventing their transcription (Figure 
1.3)45. If this is in fact the case, disruption of the LxCxE binding cleft would be 
unnecessary as loss of E2F interaction with pRB would prevent LxCxE interactors from 
associating with E2F target genes. This begs the question, why are LxCxE interactors 
also perturbed by pRB phosphorylation? The disruption of the LxCxE binding cleft by 
pRB compaction following phosphorylation suggests that the LxCxE binding cleft can 
facilitate interactions when not bound to DNA that are important to the tumor-
suppressive function of pRB. 
1.14 Cell cycle entry as controlled by pRB 
Once a cell is stimulated to divide, a variety of signal transduction pathways are 
activated leading to cellular division. One critical pathway involved in transducing 
extracellular signals to trigger cellular division is the Ras/MAPK pathway2. Following 
stimulation by growth factors, membrane spanning cell surface receptor tyrosine kinases 
(RTKs) lead to the activation of Ras, triggering a signaling cascade which ultimately 
results Myc activation2. Myc then initiates a transcriptional program that promotes cell 
cycle progression69. This includes the upregulation of Cyclins, E2Fs, as well as the 
repression of CKIs69. The increased CDK4/6 activity through the increased expression of 
Cyclin D promoted by Myc activity results in the phosphorylation of pRB at several CDK 
sites located in unstructured regions of the protein70,71. These phosphorylation events 
trigger the conformational shift in pRB described above resulting in the disruption of 
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pRB function45. This structural change prevents both the pocket of pRB from associating 
with E2Fs as well as the large variety of LxCxE interactors from binding the LxCxE 
binding cleft45. Activator E2Fs are then free to recruit transcriptional co-factors 
enhancing the transcription of S-phase genes including Cyclins, replication complex 
members, and many other genes required for cellular division54. Critically, one such E2F 
target gene is CCNE1 which encodes for Cyclin E which together with CDK2 forces the 
G1 to S-phase transition committing the cell to the cell cycle (Figure 1.5)67,72. This feed 
forward loop ensures that the cell proceeds through the entire cell cycle regardless of 
continual stimulation73. This allows pRB to translate the various growth stimulating 
signals into an all or nothing E2F response, which, once activated, will complete the cell 
cycle independent of stimulation by serum or other growth factors73.  Taken together this 
suggests that pRB is a critical gate-keeper of the G1 to S-phase transition, and ultimately 
the cell division cycle. 
The study of pRB-E2F interactions has largely focused on the transition from the G1 
to S-phase of the cell cycle. As such the majority of experiments have been performed in 
quiescent cells that are stimulated to divide43. Coincident with cell cycle entry, pRB 
becomes hyperphosphorylated and E2F target gene expression levels increase74,75. 
Importantly, activator E2Fs (E2F1-3) have been shown to be required to allow for cell 
cycle entry56,74,75. Finally, the overexpression of E2F1 in quiescent cells was sufficient to 
drive the cell into S-phase as denoted by BrdU incorporation76. While this model has 
been well established for cell cycle entry far fewer studies have looked at cell cycle exit, 
an oversight pointed out in 1998 by Dyson in his seminal review43. 
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Figure 1.5: Schematic representation of the pRB pathway. 
The activity of pRB is controlled largely by phosphorylation. When there is increased 
Cyclin D/CDK4 activity due to increased expression or loss of p16 inhibition, pRB 
becomes hyperphosphorylation. This allows for the release of E2F transcription factors 
and the upregulation of S-phase genes including Cyclin E. Cyclin E/CDK2 complexes are 
responsible for further inactivating pRB through hyperphosphorylation as well as driving 
the cell into S-phase. 
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1.15 Consequences of pRB loss in vivo 
In 1992, to better understand the role of the Rb1 gene, three knockout mouse models 
of pRb loss were created resulting in animals which do not express pRb77-79. Loss of pRb 
is relatively well tolerated in early embryogenesis and Rb1-/- knockout embryos are 
indistinguishable from littermates77. However, loss of pRb results in embryonic lethality 
between E14 and E15 days of gestation77. This is largely attributed to hyperplasia 
occurring in the trophoblasts of the placenta80. This overgrowth leads to decreased space 
between the mother and fetal blood supply and subsequent reduction of nutrient flow to 
the developing embryo80. Interestingly if the Rb1-/- embryo is supplemented with a 
normal placenta the embryos can develop normally until birth80,81. These animals die 
shortly after birth due to inadequate skeletal muscle development in the diaphragm 
preventing the newborn lungs from inflating properly81. Additionally, fibroblasts isolated 
from Rb1-/- embryos have demonstrated that pRB plays key roles in the ability of cells to 
respond appropriately to a variety of cellular stressors including DNA damage, serum 
starvation, TGF-β treatment, expression of p16 as well as others64,82-84. Consistent with 
the established paradigm of pRB-mediated regulation of cell cycle control through the 
disruption of E2F driven transcription, codeletion of E2f1 or E2f3 with Rb1 loss, partially 
rescued pRb deletion resulting in prolonged viability of embryos extending life from E14 
to E17.5 days54,85,86.  
While complete Rb1 knockout is embryonic lethal, mice which are heterozygous 
for the Rb1 gene (Rb1+/-) do develop normally into adulthood77,87,88. Beginning around 
300 days of age Rb1+/- mice develop pituitary adenocarcinomas arising from the 
intermediate lobe of the pituitary64,87-89. Importantly, this occurs following loss of 
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heterozygosity of the wild-type allele of Rb190. This genetic alteration results in an Rb1 
null cell which has already bypassed all the developmental problems associated with Rb1 
homozygous deletion77. These cells then have perturbed cell cycle control, and following 
additional mutations in critical pathways can develop into pituitary tumors64,87,88. 
Furthermore, several groups have created conditional knockout models of pRB91-94. 
While it is beyond the scope of this thesis to discuss all the various conditional knockouts 
of pRb, some studies have demonstrated a loss of cell cycle control and hyperplasia in 
conjugation with deregulation of E2F transcription factor activity however, this is far 
from consistent and E2F target gene expression changes are not always the most dramatic 
shifts in the transcriptome91-94. 
Lastly, 2 groups in 1994 independently developed chimeric mouse models of pRb 
loss95,96. These animals contained cells harboring homozygous deletion of the Rb1 gene 
as well as heterozygous Rb1+/- cells95,96. Surprisingly, the contribution of some 
heterozygous Rb1+/- cells is sufficient to allow for proper development, despite the a 
large proportion of Rb1-/- cells in these mice making up 40% to 80% of a given tissue96. 
Similar to Rb1+/- mice these chimeric animals develop pituitary adenocarcinomas at an 
accelerated rate96. These studies demonstrate that even in the case of a complete loss of 
pRb, cells they can still differentiate and contribute to tissues in an adult animal.  
Overall, mouse models lacking pRb have played a significant role in determining the 
effect of pRB on development as well as tumorigenesis. Homozygous deletion of Rb1 is 
embryonic lethal in mice due to hyperplasia of the placenta and subsequent starvation of 
the embryo77,80. Interestingly, Rb1+/- animals bypasses the embryonic lethality, however 
eventually loss of the wild-type allele of Rb1 allows for the development of a tumor 
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phenotype later in life (~300 days)64,87-89. This type of genetic background is more 
representative of children with retinoblastoma. Most often, these children inherent one 
copy of the RB1 gene which is mutated and develop the second mutation somatically25. 
This eventually leads to the formation of the retinoblastoma. This finding that both alleles 
of the Rb1 gene must be deleted to form tumors in mice supports Knudsen’s two hit 
hypothesis25,90.  
1.16 Regulation of pRB through CDK phosphorylation 
pRB is typically regulated through phosphorylation67. This phosphorylation leads to 
the compaction of the pRB protein blocking the various binding surfaces in the large 
pocket, releasing E2Fs, and allowing the cell to move into S-phase (Figure 1.4)45. These 
phosphorylation marks are added by a family of proteins known as the Cyclin dependent 
kinases (CDKs)68. These complexes are made up of two individual proteins, the catalytic 
CDK protein and a regulatory Cyclin component68. In general, CDK levels are relatively 
stable throughout the cell cycle however the specific Cyclins associated with them 
fluctuate greatly depending on the phase of the cell cycle (Figure 1.6)4. This ensures that 
the correct CDK is activated during the right phase of the cell cycle, resulting in one 
complete round of DNA synthesis and division only when instructed to do so by various 
signals. 
1.17 CDK activity throughout the cell cycle 
There are 4 main Cyclin/CDK pairs that regulate the mammalian cell cycle68. 
Beginning in G1, a variety of growth factors such as EGF bind to receptors on the surface 
of cells2. This signal is then propagated through a number of signalling kinases, in the  
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Figure 1.6: Expression patterns of various Cyclins control cell cycle progression. 
Idealized expression patterns of 4 key Cyclins over the course of the cell cycle. Once 
expressed each Cyclin can associate with its catalytic partner CDKs facilitating the 
phosphorylation of substrates necessary for that particular section of the cell cycle. In 
general, Cyclin D is expressed beginning in G1 and persists through mitosis. By 
comparison Cyclin E, Cyclin A, and Cyclin B all peak at more defined times, G1-S, G2, 
and mitosis respectively. 
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case of EGF, the Ras, Raf, MAPK pathway97. The expression of Cyclin D is then 
upregulated, which can bind to its catalytic subunits, CDK4 or CDK697. This complex is 
then able to bind to and phosphorylate pRB98. E2F-DP transcription factors are then free 
to activate transcription of S-phase required genes98. One critical gene activated by E2F 
transcription factors is CCNE1 which encodes for the Cyclin E protein72. Once in 
complex with CDK2, Cyclin E/CDK2 phosphorylates a variety of targets that are 
necessary for DNA synthesis including the firing of pre-replication complexes68,99. 
Importantly, Cyclin E/CDK2 complexes also phosphorylate pRB ensuring that the cell 
continues through S-phase and completes cellular division before returning to a G1 
state100. As the cell progresses through DNA synthesis phase, Cyclin A, another E2F 
target gene, replaces Cyclin E as the regulator subunit of CDK268,101. Finally, after the 
cell has completed DNA synthesis and traversed the G2 phase, the final of the 4 main 
Cyclin/CDK complexes Cyclin B and its binding partner CDK1 drive the cell through 
mitosis68. These 4 complexes together control the cell cycle68. Importantly, cell cycle 
regulation by Cyclin A/CDK2 and Cyclin B/CDK1 complexes can only be temporarily 
stalled via the DNA damage and spindle assembly checkpoints19,21. This leaves regulation 
at the G1 to S-phase boundary the critical road block in the prevention of aberrant cell 
growth24. As such this transition is highly regulated through both Cyclin/CDK activity as 
well as by pRB, and pathways influencing these genes are often targets of cancer causing 
mutations30,102. These two pathways form a critical hub through which a variety of signals 
are funneled determining if the cell will divide or not. 
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1.18 Cyclin dependent kinase inhibitors and their role in 
regulating the cell cycle. 
Transcriptional control of Cyclins ensures that the appropriate CDK is activated 
during the proper phase of the cycle103. In addition to this regulation, Cyclin/CDK 
complexes are further controlled by 2 families of CKIs which further influence the cell 
cycle104,105. The two families are divided up based on the CDK complexes which they can 
inhibit104,106. First, the INK4 family consists of 4 members p14, p15, p16, and p18, all of 
which are specific inhibitors of Cyclin D/CDK4/6 complexes and are involved in cellular 
senescence, apoptosis and DNA repair (Figure 1.7)105,106. As these proteins specifically 
influence Cyclin D/CDK4/6 activity, their role is primarily contained to the G1 phase of 
the cell cycle105,106. The second family of CKIs is the CIP/KIP family which is made up 
of p21, p27 and p57 (Figure 1.7)104. These proteins more broadly influence the activity 
of CDKs as there can inhibit all 4 major Cyclin/CDK complexes which drive the 
mammalian cell cycle68,104. Similarly, CIP/KIP family proteins are responsible for 
arresting the cell in response to a variety stimuli such as genetic insults or loss of mitogen 
signalling107. This family is more universal than the INK4 family as they can inhibit 
many CDKs and as such can elicit a cell cycle arrest in multiple phases of the cell 
cycle108.  
While the three members of the CIP/KIP family of proteins are capable of interacting 
with the same Cyclin/CDK complexes, each member is expressed in different 
circumstances104. In particular, p21 is critical to the DNA damage response and its 
expression is directly regulated in response to p53 activation109. By contrast, p27 is more 
typically associated with the G1 phase of the cell cycle and is involved in cell cycle arrest  
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Figure 1.7: Schematic representation of the G1-S-phase transition of the cell cycle. 
Following mitogenic stimulation in the G1 phase of the cell cycle an increase in Cyclin 
D/ CDK4/6 activity hyperphosphorylates pRB, releasing the E2F/DP transcription factor. 
Once free, E2F upregulates several genes including CCNE1, encoding for Cyclin E, 
which together with CDK2 can also phosphorylate pRB. This creates a feed forward loop 
ensuring that once started the cell cycle is completed. In addition, two families of Cyclin 
dependent kinase inhibitor CKIs restrict the activity of Cyclin/CDKs. The Ink4 family 
consists of p14, p15, p16, and p18, and inhibits Cyclin D/ CDK4/6 complexes. The 
CIP/KIP family consists of p21, p27, and p57 which can broadly inhibit Cyclin/ CDK 
complexes. The activity of these CKIs are influences by both extracellular cues such at 
mitogen deprivation as well as intracellular cues such as DNA damage. The overall 
balance of Cyclin/CDKs and CKIs determine whether the cell will enter the cell cycle. 
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following growth factor deprivation, TGF-β treatment, as well as contact inhibition104. 
Finally, p57 appears to be involved primarily in development as p57 knockout animals 
die immediately following birth due to several developmental defects including cleft 
plate, abdominal muscle defect as well as skeletal defects104. The balance of 
Cyclin/CDKs and CKI expression together determine the overall activity of the various 
Cyclin/CDK complexes and ultimately whether the cell will undergo division104,105,108. 
Additionally, this interplay also underpins the cellular arrest in response to various 
stimuli such as DNA damage, quiescence induction and differentiation104.  
  The precise balance of Cyclin/CDK complexes to CKIs is critical to determine 
whether a cell will traverse the G1 to S phase checkpoint. Once kinase activity, in 
particular Cyclin E/CDK2, reaches a certain threshold the cell activates a feed forward 
cascade which commits the cell to division110. This feed forward loop is initiated by 
Cyclin E/CDK2-mediated phosphorylation of pRB110. As discussed above these 
phosphorylation events result in a conformational change in the pRB molecule, releasing 
E2Fs causing the expression of CCNE1 and CCNA2, both of which complex with CDK2 
further phosphorylating pRB molecules45,72,101. This loop ensures that pRB is maintained 
in a hyperphosphorylated state throughout S-phase and G2 allowing for the expression of 
E2F target genes which are needed to complete DNA replication and the cell cycle67. In 
addition to phosphorylating pRB, Cyclin/CDKs also target a variety of cellular proteins, 
including transcription factors and most importantly activate a cascade leading to the 
firing of replication origins, beginning the process of DNA replication68,111. Importantly, 
while pRB can influence cell cycle progression at the G1 to S-phase boundary, ultimately 
S-phase entry is determined by the overall level of CDK activity and in particular Cyclin 
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E/CDK2 activity (Figure 1.7)68,111. Therefore, the combined inputs of pRB-mediated 
repression of CCNE1 and the expression of CKIs control CDK activity and cell cycle 
progression. Both the pRB and CKI pathways play integral roles in regulating CDKs and 
the cell cycle and the interconnectedness of these two pathways, suggests that there could 
be some level of redundancy involved between them (Figure 1.7). 
1.19 Disruption of the pRB pathway in cancer 
Given that pRB acts as a critical gate-keeper to cellular division it is perhaps 
unsurprising that the pRB pathway is perturbed in a large majority of human cancers30. 
Interestingly however, mutations in pRB itself is relatively rare outside of small cell lung 
cancer, retinoblastoma and osteosarcoma30. Instead upstream disruption of the kinases 
involved in phosphorylating pRB are targeted for mutation resulting in constitutive pRB 
hyperphosphorylation, inhibiting its various functions30. The complete disruption of the 
pRB protein by phosphorylation in the majority of cancers suggests pRB performs 
multiple critical functions to maintain cell cycle control and is not limited solely to the 
repression of E2Fs30. 
Early Saos-2 cell cycle arrest assays demonstrated that the minimal region of pRB 
capable of arresting the cell cycle was also capable of binding E2Fs49,50. Importantly, this 
fragment also contains the LxCxE binding cleft which binds several cellular proteins 
(Figure 1.2B)47,49,50. More recently, Soas-2 arrest assays were performed using the partial 
penetrant familial retinoblastoma mutant RB1R661W 112. This mutant has defective binding 
to E2F-DP heterodimers and gives rise to benign retinomas and rare retinoblastoma in 
children112,113. Surprisingly however, this mutant version of pRB is still capable of 
restricting the cell cycle when expressed in Saos-2 cells despite the apparent lack of E2F 
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repression112. It is important to note, however, that the RB1R661W mutant does have partial 
disruption of LxCxE interactions and the G1 cell cycle arrest conveyed in Saos-2 cells is 
unstable112. These results provided an important basis for the study of pRB-mediated cell 
cycle control independent of E2F, however given the caveats associated with the 
RB1R661W mutation a new model was needed. 
1.20 Development of the Rb1G/G mouse model 
Building on the results from Sellers et al. demonstrating that the E2F-binding 
deficient mutant RB1R661W could induce a G1 cell cycle arrest in Saos-2 cells, Cecchini et 
al. developed a targeted mutation in the pRB pocket which successfully disrupted the 
ability of pRB from associating with E2Fs through the pocket domain (See appendix 
A)64,65. This mutation referred to as the RB1G mutation contains two amino acid 
substitutions (K467E and R548E) which change key pocket residues from a basic charge 
to an acidic one64. This therefore prevents the pocket from binding to the acidic regions in 
the transactivation domain of E2F leading to charge repulsion and an inability to bind 
pRB65. As expected, cells homozygous for the Rb1G mutation do show a loss of pRb 
binding to E2F target gene promoters as pRb can no longer be carried to promoters via 
E2Fs64. Consistent with this finding, the depletion of pRb from the DNA results in an 
increase in the expression of E2F target genes64. Surprisingly, despite the loss of E2F 
repression caused by the Rb1G mutation, these cells eventually give rise to viable animals, 
which display no overt phenotype64. These mice developed normally, are fertile and show 
no tumor phenotype or lifespan changes64. This is in direct contrast to complete knockout 
of the Rb1 gene, which, as previously mentioned is embryonic lethal between E14 and 
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E1577. Taken together, this suggests that E2F regulation by pRB is dispensable for pRB-
mediated development and tumor-suppression. 
The role for pRB in cell cycle control has been well established as cells lacking pRB 
are not capable of appropriately restricting cell cycle entry following treatment with a 
variety of conditions82-84. Interestingly, when Rb1G/G cells were deprived of serum or 
treated with ionizing radiation, a successful G1 cell cycle arrest occurred as efficiently as 
wildtype cells64. Furthermore, even in this context, Rb1G/G cells still maintain elevated 
levels of E2F target gene expression, equivalent to Rb1-/- cells which failed to arrest64. 
These experiments indicated that E2F regulation by pRB is dispensable to enact a G1 cell 
cycle arrest in response to cellular stressors. While this finding was surprising, it is 
important to note that the majority of  studies highlighting the importance E2F in cell 
cycle focus on its ability to stimulate the entry into S-phase of the cell cycle43. However, 
consistent with the importance of E2F target gene induction in cell cycle entry, Rb1G/G 
cells stimulated to divide from a quiescent state entered the cell cycle far earlier than 
wildtype cells and at a similar rate to Rb1-/- cells64. 
This study identified that the linear model of pRB regulation of the cell cycle through 
the repression of E2Fs is incomplete, at least for cell cycle exit64. Therefore, additional 
pathways must be active to arrest the cell following treatment with these agents. As 
discussed above, Cyclin/CDK complexes are crucial to cell cycle progression68. When a 
cell must arrest the cell cycle due to DNA damage or serum deprivation CKIs become 
active, inhibiting the activity of Cyclin/CDK complexes104,105. This then leads to the 
hypophoshorylation of pRB preventing the activity of E2F transcription factors. 
Additionally, the inhibition of Cyclin E/CDK2 by CKIs prevent the firing of replication 
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origins which is the definitive transition from G1-S phase111. Furthermore, as Cyclin E 
expression is regulated by E2F activity, Cyclin E/CDK2 therefore is upstream and 
downstream of pRB regulation72. Therefore, in the context of Rb1G/G cells, perhaps the 
arrest is achieved through the direct inhibition of Cyclin E/CDK2, independent of E2F 
repression. Lastly, this function must be pRB dependent as Rb1-/- cells are incapable of 
initiating an arrest under the same conditions that lead to an arrest in Rb1G/G cells64. 
1.21 E2F independent regulation of the cell cycle by 
pRB 
One possible explanation for the G1 cell cycle arrest in Rb1G/G cells which is 
independent of E2F regulation is through the CKI p2764. Previous work has identified 
that RB1R661W can initiate a G1 cell cycle arrest in Soas-2 cells despite lacking the ability 
to associate with E2Fs112. Ji et al. confirmed this finding and showed that both wild-type 
RB1 and the mutant RB1R661W increased the protein level of p27 coincident with cell cycle 
arrest in Saos-2 cells114. Higher expression of p27 in turn can inhibit the activity of 
Cyclin E/CDK2 and prevent cell cycle progression68. Importantly, p27 has also been 
implicated in regulating a variety of oncogenic and tumor-suppressive functions in 
addition to CDK inhibition115. These non-canonical functions of p27 will be discussed in 
greater detail at the end of this thesis as they will be more relevant in the context of some 
experiments performed. Finally, given the inability of RB1R661W to associate with E2Fs, 
any regulation must exist independent of transcriptional control113. 
1.22 Modulation of p27 activity through the cell cycle. 
The level of p27 is generally controlled by the rate at which it is degraded (Figure 
1.8)99. During cell cycle initiation, p27 is degraded through the combined activity of  
33 
 
 
 
 
 
 
 
 
 
 
Figure 1.8: Schematic representation of E2F-independent pRB-mediated cell cycle 
regulation through the pRB-SKP2-p27 axis. 
pRB associates with both the anaphase promoting complex containing Cdh1 (APCCdh1) 
and SKP2. By serving as a scaffold, pRB facilitates poly-ubiquitination (Ub) of SKP2 by 
the APCCdh1. The degradation of SKP2 prevents p27 polyubiquitination by the SCF 
complex as SKP2 is required for p27 targeting. The pRB-mediated ubiquitination and 
subsequent degradation of SKP2 by the APCCdh1 and the proteasome results in the 
stabilization of p27 and inhibition of the cell cycle. 
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CDK phosphorylation and degradation by the proteasome allowing for the cell to 
progress into S-phase99. This degradation is primarily controlled by the SCF complex 
containing the targeting E3 ligase SKP2116. Following CDK phosphorylation of p27, 
SKP2 can associate with p27 resulting in the poly-ubiquitination of p27 targeting it to the 
proteasome for degradation116. As SKP2 is the protein involved in targeting p27 for poly-
ubiquitination, this reaction is controlled by the level of available SKP2 to associate with 
the SCF complex116.  
The involvement of pRB in regulating p27 in this manner has been analyzed in 
two landmark studies114,117. Collectively, these reports demonstrate that pRB is capable of 
binding to both SKP2 as well as the Cdh1 containing APC complex (APCCdh1) (Figure 
1.8)114,117. Importantly, APCCdh1 has ubiquitin ligase activity and is active in G1 to poly-
ubiquitinate a large variety of proteins, including those involved in mitosis leading to 
their degradation118. This ensures that the cell is returned to a G1 state prior to re-entering 
the cell cycle118. One such target of the APCCdh1 is SKP2, which when degraded, 
effectively stabilizes p27 (Figure 1.8)116,119. The finding that pRB can bind to both 
APCCdh1 and SKP2 suggest that pRB may be acting as a scaffold to facilitate the 
degradation of SKP2114,117. Furthermore, the ability of pRB to interact with SKP2 and 
stabilize p27 is maintained when the RB1R661W is expressed in Soas-2 cells indicating that 
E2F binding is not required for this process114. 
This second axis of pRB-mediated cell cycle control is particularly intriguing as it 
appears to be E2F independent and functional in cells containing RB1R661W114. Previous 
work has created a mouse model harboring the equivalent mutation to R661W in mice 
(Rb1R654W) which displayed a similar phenotype to Rb1-/- animals dying embryonically 
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due to placental defects120. This effect is less severe however as Rb1R654W animals survive 
slightly longer dying around E15 to E17120. Importantly, in addition to disrupting pRB-
E2F interactions, this mutation also partially disrupts LxCxE interactors which may also 
have roles in regulating the cell cycle121. By contrast, the Rb1G/G mutant mice developed 
by Cecchini et al. contain a much more targeted mutation which specifically eliminated 
pRB-E2F interactions through the general site while maintaining LxCxE interaction and 
the pRB-E2F1 specific interaction64. Moreover, Rb1G/G mutant animals are viable and 
show no long-term consequences of E2F deregulation64. This implies that pRB must be 
playing additional roles to regulate the cell cycle independent of E2F repression. The 
pRB-SKP2-p27 axis of regulation discussed above is an intriguing possibility to account 
for the dispensability of pRB-E2F interactions (Figure 1.8). The Rb1G/G model allows for 
the unique opportunity to study E2F independent regulation of cell cycle control and 
tumor suppression by pRB, including the pRB-SKP2-p27 axis, in an in vivo context. 
1.23 Objectives 
One of the main functions of pRB-mediated cell cycle control is the repression of E2F 
transcription factors preventing the upregulation of genes required for S-phase 
progression10. However, considering recent evidence discussed in the introductory 
chapter it is now clear that explanation is not complete64,112,114. Instead, it suggests that 
pRB can regulate the cell cycle though multiple pathways influencing the G1 to S-phase 
transition. The Rb1G/G mouse model developed in our lab provides an excellent tool to 
study these alternative functions of pRB64. Given the normal development and lifespan of 
the Rb1G/G mice we can combine these mice with other mutant mouse strains to attempt 
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to recapitulate the phenotype of Rb1-/- mice thereby accounting for all the functions of 
RB-mediated cell cycle control and tumor suppression64,77. 
In the first chapter I characterized the pRB-p27 axis of pRB-mediated cell cycle 
control. I hypothesized that the maintenance of cell cycle control in Rb1G/G cells is due to 
the stabilization of p27 mediated by the LxCxE binding cleft on pRB114,117. By combining 
our Rb1G/G mutant mice with those harboring a null allele for p27 (Cdkn1b-/-), we could 
address the importance of the pRB-p27 axis of pRB tumor suppression both in cell 
culture and in vivo122. Using double mutant Rb1G/G; Cdkn1b-/- cells as well as single 
mutant controls I analyzed the ability of cells to arrest the cell cycle under different 
treatment conditions. Furthermore, we were then able to confirm these results in the 
double mutant Rb1G/G; Cdkn1b-/- mice. These results will be discussed in detail in chapter 
2 of this thesis. 
In addition to the pRB-mediated regulation of E2F and p27, several other proteins 
interact with pRB and as such may influence the cell cycle or tumor-suppressive 
properties of pRB47,51,62. As such we hypothesized that the three distinct binding surfaces 
in the pRB large pocket discussed above play a role in regulating the function of pRB. 
Using mutations developed in our lab we could individually and simultaneously disrupt 
the general pRB-E2F pocket, the LxCxE binding cleft, and the pRB-E2F1 specific 
interaction62,65,123. Following expression of these mutant versions of RB1 in Saos-2 cells 
we can directly measure the contribution that each individual binding surface makes 
towards pRB-mediated G1 arrest. Further, by intercrossing our Rb1G/G; Cdkn1b-/- mice 
generated in chapter two into the E2f1 null background we could create an in vivo model 
of disruption of all three binding surfaces. Analysis of livers was carried out to determine 
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if we had in fact recapitulated Rb1 loss in adult tissues. A detailed description of the 
results of these experiments can be found in chapter 3 of this thesis. 
pRB pathway mutations have been well documented in a variety of human cancers30. 
As discussed in the introduction, the majority of these mutations occur upstream of pRB 
leading to hyperphosphorylation and inactivation of the pRB protein30. This finding 
suggests that single point mutations which target a specific domain such as the E2F 
binding pocket on pRB would be ineffective in eliminating pRB functionality. This 
hypothesis is further collaborated by the lack of effect on tumor suppression displayed by 
the Rb1G mutation64. However, the disruption of pRB-E2F interactions would reduce the 
pathways through which pRB can regulate the cell cycle and thus we hypothesized that 
Rb1G/G would display increased sensitivity to tumorigenesis when combined with 
activated oncogenes or loss of tumor-suppressors.  In chapter 4 I tested this hypothesis by 
combining our Rb1G/G mutant animals with three different genetic backgrounds. The 
Rb1G/G mutation was introduced into mouse lines containing oncogenic KrasG12D, or 
deletions of p53 or p21 tumor suppressors64,124-127. Detailed explanations of the results of 
these experiments are presented in chapter 4. 
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Chapter 2  
2 Interchangeable roles for E2F transcriptional repression 
by the retinoblastoma protein and p27KIP1-CDK 
regulation in cell cycle control and tumor suppression. 
2.1 Abstract 
The mammalian G1-S phase transition is controlled by the opposing forces of Cyclin 
dependent kinases (CDK) and the retinoblastoma protein (pRB).  Here we present 
evidence for systems level control of cell cycle arrest by pRB-E2F and p27-CDK 
regulation.  By introducing a point mutant allele of pRB that is defective for E2F 
repression (Rb1G) into a p27KIP1 null background (Cdkn1b-/-), both E2F transcriptional 
repression and CDK regulation are compromised.  These double mutant Rb1G/G; Cdkn1b-
/- mice are viable and phenocopy Rb1+/- mice in developing pituitary adenocarcinomas, 
even though neither single mutant strain is cancer prone.  Combined loss of pRB-E2F 
transcriptional regulation and p27KIP1 leads to defective proliferative control in response 
to various types of DNA damage.  In addition, Rb1G/G; Cdkn1b-/- fibroblasts immortalize 
faster in culture and more frequently than either single mutant genotype.  Importantly, the 
synthetic DNA damage arrest defect caused by Rb1G/G; Cdkn1b-/- mutations is evident in 
the developing intermediate pituitary lobe where tumors ultimately arise.  Our work 
identifies a unique relationship between pRB-E2F and p27-CDK control and offers in 
vivo evidence that pRB is capable of cell cycle control through E2F independent effects. 
2.2 Introduction 
Regulation of the cell cycle is critical to maintain cellular homeostasis and to 
prevent the development of cancer 1.  Mammalian cell division is primarily controlled at 
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the G1-S phase transition, and the moment of commitment is often described as the 
restriction point 2.  Commitment to enter the cell cycle is controlled by two opposing 
forces; the retinoblastoma protein family (including pRB) that blocks entry, and Cyclin 
Dependent Kinases (CDKs) that drive advancement into S-phase 3.  The RB protein 
antagonizes S-phase entry by repressing E2F regulated genes necessary for DNA 
replication 4.  Working in opposition to pRB are CDKs 5, in particular Cyclin D and E 
associated kinases phosphorylate and inactivate upstream regulators of cell cycle entry 
including pRB and p27KIP1, as well as stimulate the activation of downstream effectors of 
DNA replication 6,7.  While this suggests CDKs control pRB, a key target gene that is 
repressed by pRB-E2F is CCNE1 that encodes Cyclin E, this creates a regulatory loop 
whereby Cyclin E/CDK2 becomes maximally active at almost the same time pRB is 
maximally phosphorylated and finally releases all E2Fs 4.  In addition, CDK2’s principal 
negative regulator p27KIP1 is phosphorylated and targeted for degradation at virtually the 
same time 8.  Due to this interplay between pRB and CDK activity, it has been difficult to 
place one upstream of the other in a regulatory pathway 4.  Numerous studies suggest that 
either pRB-E2F or p27KIP1-CDK2 interactions are essential for controlling quiescence or 
cell cycle entry commitment 9-17. For this reason, control of the G1-S phase transition 
remains unclear.  Furthermore, since much of the literature investigating G1-S regulation 
focuses on regulatory events during cell cycle entry 4,18, this leaves the roles for pRB-E2F 
and p27KIP1-CDK interactions in cell cycle exit much less explored. 
Cell cycle arrest by pRB has long been attributed to E2F regulation because the 
minimal deletion mutant of pRB that is capable of binding E2Fs can block proliferation 
of Saos-2 cells 19,20.  These studies revealed a close correlation between pRB-E2F 
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binding, transcriptional repression, and cell cycle arrest 20,21.  However, E2F binding 
mutants of pRB have a surprising retention of growth control activity in this assay 22-24, 
suggesting that other mechanisms may contribute.  Given that cell cycle control 
ultimately impinges on CDK regulation, a number of studies have connected pRB growth 
arrest activity in Saos-2 cells to CDK regulation through p27KIP1 25-27.  First, E2F binding 
deficient mutants of pRB induce p27KIP1 expression in Saos-2 cell cycle arrest assays, and 
p27 expression is required for these mutants of pRB to induce arrest 27.  Secondly, pRB 
stabilizes p27KIP1 expression during induction of a G1 arrest quite rapidly, and this 
precedes the decline in E2F regulated targets by at least 24 hours, suggesting CDK 
regulation occurs first 26.  Moreover, Ji et al., also demonstrated that pRB is capable of 
binding and inhibiting the function of Skp2, the E3 ligase targeting subunit responsible 
for poly-ubiquitination of p27 26.  Consistent with this, the increases in p27 levels seen 
following pRB expression in Saos-2 cells correlate with a decrease in Skp2 levels 25.  
Binne et al., showed that APC complexes containing Cdh1 are capable of using pRB as 
an adaptor for Skp2 binding and ubiquitination, thereby stimulating Skp2 degradation and 
promoting the stabilization of p27 25. Collectively, these studies connect pRB regulation 
of the cell cycle to p27.  However, the shortcoming of this work is its dependence on 
ectopic pRB expression, a physiological context where pRB regulation of p27 genuinely 
contributes to proliferative control decisions has yet to emerge.  A number of genetic 
crosses indicate that Skp2 loss can suppress pituitary tumorigenesis in Rb1+/- mice 28, 
even in combination with p53 deficiency 29. However, efforts to find p27 dependent 
growth arrest in tissues of these mice have been confounded by other cellular effects such 
as apoptosis in the intermediate lobe of the pituitary 28.  This has prevented the 
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observation of proliferative control decisions in these cells that use a pRB-p27 axis.  For 
this reason, the pRB-p27 connection in proliferative control remains compelling, but its 
lack of detection in an endogenous scenario is a critical gap in our knowledge. 
To study E2F independent functions of pRB at an endogenous level, we 
developed a mutant mouse model in which pRB binding to E2Fs is disrupted by R461E 
and K542E mutations (called Rb1G) 30. Importantly the Rb1G mutant protein is expressed 
at wild type levels and makes normal interactions with LXCXE motif containing proteins 
30. Surprisingly, we found that this mutation had little effect on control of cell 
proliferation, as Rb1G/G fibroblasts are capable of responding to serum starvation, p16 
expression, DNA damage, and myogenic differentiation and in all cases show wild type 
responses 30. In this study, we find that p27 expression levels are higher in Rb1G/G 
fibroblasts. In addition, double mutant Rb1G/G and p27 deficient cells are defective for 
growth arrest in response to DNA damage in a manner that resembles Rb1-/- cells, 
including misregulation of CDK2 activity. Furthermore, while developmentally 
unremarkable, Rb1G/G; Cdkn1b-/- mice display a highly penetrant tumor phenotype. 
Together our study demonstrates systems level redundancy between pRB-E2F regulation 
and p27-CDK2 control, as the combined loss displays cell cycle defects that are absent 
from either single mouse mutant. In addition, this work provides proof of principle for 
transcription independent coordination between the RB and the CDK pathways in 
endogenous growth control. 
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2.3 Materials and Methods 
2.3.1 Cell culture methods.  
Mouse embryonic fibroblasts (MEFs) were derived from E13.5 embryos of the 
indicated genotypes. Asynchronous cells were cultured using standard methods in 
Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum (FBS), 2mM L-
glutamine, 50U/ml penicillin and 50µg/ml streptomycin. Cells subjected to serum 
deprivation were cultured in the above media however only containing 0.1% FBS.  
2.3.2 DNA damage induction.  
MEFs subjected to gamma irradiation were plated at low density at passage 4. The 
next day media was changed prior to exposure to a cobalt 60 source until a dose of 15Gy 
was received. Media was changed again the next morning and cells were harvested 48 
hours after treatment. Cells treated with DNA damaging agents cisplatin and H2O2 were 
plated at low density at passage 4 then the next day switched to media containing the 
indicated drug at a concentration of 1µM for cisplatin and 250µM for H2O2. Cells were 
incubated in the drug containing media for 48 hours before harvest for downstream 
applications. 
2.3.3 Cell cycle analysis.  
Cells were pulsed with BrdU under different growth conditions: asynchronous 
culture, serum deprived, serum stimulated, or various sources of DNA damage for a 
duration of 2 hours. Cell cycle analysis was then carried out following previously 
published protocols 31.   
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2.3.4 mRNA quantitation.  
RNA isolation was carried out using Trizol reagent according to manufacturers 
instructions and previously published protocols 30. mRNA levels of p27 were analyzed by 
qRT-PCR using iQ Sybr-green Super Mix (Bio-Rad) and the following primers against 
p27 and GAPDH: p27 Fwd (5`AGATACGAGTGGCAGGAGGT 3`), p27 Rev (5` 
ATGCCGGTCCTCAGAGTTTG 3`), GAPDH Fwd (5` 
GCACAGTCAAGGCCGAGAAT 3`), GAPDH Fwd. (5` 
GCCTTCTCCATGGTGGTGAA 3`). Expression levels of common E2F target genes: 
Pcna1, Ccne1, Ccna2, Tyms, Rbl1, and Mcm3 were determined using the Quantigene 
Plex 2.0 reagent system from Affymetrix as previously described 32. Expression levels 
were normalized to Actin. 
2.3.5 3T3 Assay.  
Passage 3 MEFs were plated at a density of 1x106 cells per 10cm culture dish in 
Dulbecco’s modified Eagle’s medium containing 10% Calf serum, 2mM L-glutamine, 
50U/ml penicillin and 50µg/ml streptomycin. Three days after plating cells were counted 
and replated at the same density, 1x106 cells per 10cm dish. This procedure was repeated 
until passage 20. Population increase was calculated according to the following formula: 
(Log10(recovered/seeded)/Log102. Cells were considered successfully immortalized if the 
population growth was positive at the end of the 20 passages. 
2.3.6 Protein interaction analysis and western blotting.  
Nuclear extracts were prepared from MEFs and western blotting was carried out 
using previously described protocols 30. Antibodies raised against p27 (C-19: sc-528) and 
Histone H3 (ab70550) were used for western blotting.  pRB containing complexes were 
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immunoprecipitated from whole cell extracts using anti-E2F3 C-18 (Santa Cruz) bound 
to G-sepharose beads (GE-healthcare).  IPs were rocked for 1h at 4°C then washed twice 
with IP wash buffer (10mM Tris pH 7.5, 200mM NaCl, 1.5mM MgCl2, 2mM EDTA, 
0.1% NP-40) and boiled in SDS-PAGE sample buffer.  Samples were western blotted 
using standard techniques. E2F3 was detected by PG37 (Upstate), pRB was detected by 
G3-245 (BD Pharmingen), and Actin was detected with monoclonal antibody AC-74 
(Sigma). 
2.3.7 Phenotypic analysis of animals.  
Cdkn1b-/- mice (B6.129S4-Cdkn1btm1Mlf/J) have been described previously and 
were obtained from Jackson Laboratory and genotyped as recommended 33. Rb1G/G mice 
were genotyped as previously described 30. All animals were housed and handled as 
approved by the Canadian Council on Animal Care. Mice were monitored for tumor 
development. Mice were sacrificed at natural endpoint. Survival data were subjected to 
Kaplan-Meier analysis, and significant differences were compared using a log rank test. 
For DNA damage experiments, pregnant mothers at day 13.5 of gestation were subjected 
to 10Gy IR followed by a 2h pulse of BrdU 4 hours after IR treatment.  
2.3.8 Histology and microscopy.  
E13.5 embryos treated with 10Gy of IR were removed from the uterus and fixed 
whole in PBS containing 4% PFA for 24h. Next, they were placed in PBS containing 
30% sucrose to dehydrate the samples for a minimum of 3 days. Embryos were then dried 
and mounted in Cryomatrix (Thermo Scientific 6769006), frozen using liquid nitrogen 
and stored at -80°C 34. Sagittal pituitary sections were cut using a Leica cryostat (CM 
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3050S) in 8µm sections and mounted on slides which were stored at -80°C. Slides were 
acclimated to room temperature prior to staining.  
For BrdU staining, slides were rehydrated in PBS and inserted into a Shandon 
Sequenza cassette holder (Thermo Scientific 73310017). 500µL of 2N HCl was added to 
the slides and incubated for 20 mins at room temperature. Slides were then washed twice 
with 0.1M Na2B4O7 pH 8.5 for 5 mins per wash. Slides were then put into a coplin jar 
containing 10mM sodium citrate pH 6 and microwaved for 10 mins on low power level, 
followed by a 20 min incubation at room temperature. Slides were washed again with 
PBS and reinserted into the Shadon Sequenza holder (Thermo Scientific 73310017). 
Slides were then washed twice with PBS containing 0.3% Triton-X. Anti-BrdU antibody 
(BD, 347580) was diluted 1 in 50 in PBS-0.3% Triton-X and incubated on slides 
overnight. The next day slides were washed three times with PBS-0.3% Triton-X then 
secondary anti-mouse fluorescein (Vector, FI-2000) was added at a dilution of 1 in 800 in 
PBS-0.3% Triton-X. Slides were then incubated in secondary for 1h in the dark. Slides 
were washed 3 times in PBS-0.3% Triton-X then counterstained with DAPI for 5 mins in 
the dark. Finally, slides were washed twice with PBS-0.3% Triton-X, twice with PBS, 
mounted with Slowfade (Thermo Scienfic S36937) and sealed.  
TUNEL staining was carried out according to manufactures instructions using In 
Situ Cell Death Detection Kit (Roche, 1168479510). Briefly, cells were rehydrated with 
PBS then permeabilized with PBS-0.3% Triton-X for 2 mins on ice then incubated for 1 
hour with TUNEL reagent. After incubation slides were washed 3 times with PBS, 
counterstained with DAPI for 5 mins followed by 2 washes with PBS-0.3% Triton-X and 
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2 washes with PBS. Slides were then mounted with Slowfade (Thermo S36937) and 
sealed. 
Images were acquired using a Zeiss Axioskop 40 microscope and Spot flex 
camera, and quantified using velocity image analysis software. (Perkin Elmer) 
2.3.9 CDK2 Kinase activity assays.  
Nuclear extracts were spun down at 14000 rpm for 30 mins to separate protein from 
cellular debris. 250µg of protein from each sample was precleared for 1 hour using 
Dynabeads rotating at 4°C. Samples were then split in half and incubated for an hour 
with Dynabeads prebound with either IgG or anti-CDK2 (Millipore). Complexes were 
then washed twice with IP wash buffer (10mM Tris pH 7.5, 200mM NaCl, 1.5mM 
MgCl2, 2mM EDTA, 0.1% NP-40) and twice with kinase buffer (50mM Tris pH 7.5, 
10mM MgCl2, 1mM DTT) and resuspended in 49µl of kinase buffer containing 4µg of 
recombinant histone H1 (Santa Cruz). 10µCi of 32P radio-labelled ATP was incubated 
with immunoprecipitates for 20 mins at 30°C, followed by boiling in SDS-PAGE buffer 
to stop the reaction. Samples were then run out on a 15% gel, stained with Coomassie to 
check for loading then dried and exposed to a phosphosensitive plate to determine 32P 
incorporation. 
2.4 Results 
2.4.1 Post-translational stabilization of p27 in Rb1G/G fibroblasts 
during quiescence.   
Our previously published analysis of Rb1G/G primary fibroblasts and mice 
indicates that loss of pRB-E2F repression fails to bypass cell cycle exit signals 30.  Figure 
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2.1 shows an example of a serum starvation arrest in which wild type, Rb1G/G, and knock 
out cells were serum starved for 60 hours.  Under these culture conditions wild type and 
Rb1G/G cells reduce BrdU incorporation equivalently, while Rb1-/- cells are defective 
(Figure 2.1A).  However, analysis of mRNA levels of common E2F target genes shows 
that Rb1G/G displays a similar defect in repression as Rb1-/- (Figure 2.1B).  Importantly, 
while cell cycle exit is normal in this scenario, pRB’s well studied role for restraining 
E2F activation during cell cycle entry following serum stimulation is compromised in 
Rb1G/G cells, and they enter the cell cycle with similar kinetics as knock out controls 
(Figure 2.1C).  Consistent with these findings, the R461E and K542E mutations encoded 
by the Rb1G allele prevent stable interactions with E2Fs.  We used immunoprecipitation 
and western blot assays to evaluate pRB-E2F3 interactions in serum starved cells and 
these reveal a robust defect (Figure 2.1D)30.  Since Rb1G/G cells are functional for cell 
cycle arrest in assays where Rb1-/- cells are not 30, we searched for parallel growth control 
mechanisms to pRB-E2F repression that are pRB dependent.  Building on previous 
findings of p27 stabilization in cancer cells and Rb1-/- MEFs, we sought to determine if 
this same effect was seen in our mutant Rb1G/G cells.  Following serum deprivation of 
asynchronously proliferating cultures, Rb1G/G MEFs demonstrated a modest increase in 
p27 protein levels coincident with G1 arrest (Figure 2.1E). Importantly, p27 mRNA 
levels quantitated by qRT-PCR remain the same as wild-type cells during serum 
deprivation, indicating that the change observed is likely due to a post-translational effect 
(Figure 2.1F).  This finding is consistent with the post-translational stabilization of p27 
observed in Saos2 cells induced to arrest following expression of E2F binding deficient 
mutants of pRB 27.  The increased p27 in response to loss of E2F regulation may be  
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Figure 2.1: Increased expression of p27 in serum starved Rb1G/G MEFs. 
(A) Fibroblast cells of the indicated genotypes were serum starved for 60 hours, pulse-
labelled with BrdU for 2 hours, followed by staining for BrdU incorporation.  The 
proportion of cells incorporating BrdU was determined by flow cytometry.  (B) 
Fibroblasts were serum starved as in A and the relative mRNA levels of the indicated 
genes was determined.  (C) Following serum starvation for 60 hours, cells were re-
stimulated to enter the cell cycle.  Cultures were pulse labeled with BrdU and harvested 
at the indicated time points and analyzed by flow cytometry.  (D) Whole cell extracts 
were prepared from serum starved wild type and Rb1G/G MEFs.  Western blots were 
performed to assess relative expression of pRB and E2F3.  Anti-E2F3 
immunoprecipitations were blotted for pRB.  (E) Immunoblotting of nuclear extracts 
isolated from serum deprived MEFs using antibodies raised against p27 and Histone H3.  
(F) Real-time quantitative PCR using primers to detect Cdkn1b.  Values are presented 
relative to GAPDH.  All error bars represent one standard deviation from the mean.  * 
indicates a significant difference from the wild type control using a t-test, p<0.05. 
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related to the ability of Rb1G/G MEFs to maintain proliferative control despite defective 
E2F binding. 
2.4.2 Rb1G/G; Cdkn1b-/- mice are highly cancer prone.  
To determine if p27 expression in Rb1G/G cells is responsible for the maintenance 
of cell cycle control, we crossed Rb1G/G mice with p27 deficient (Cdkn1b-/-) animals.  
Compound mutant mice display similar viability at weaning as the Rb1G/G genotype alone 
and without obvious anatomical defects, suggesting the combination of Rb1G/G and 
Cdkn1b-/- deficiency is no different than either single mutant alone (Figure 2.2A, Table 
2.1)30.  While double mutant Rb1G/G; Cdkn1b-/- mice show normal development, we aged 
cohorts of double and single mutant mice and discovered that Rb1G/G; Cdkn1b-/- mice 
succumb to pituitary tumors with an average tumor free survival of 214 days (Figure 
2.2B).  Necropsies of these mice revealed pituitary tumor masses characteristic of Rb1 
deficient animals (Figure 2.2C).  By comparison, neither Rb1G/G nor Cdkn1b-/- mice 
displayed cancer susceptibility (Figure 2.2BC), and this is consistent with prior reports 
of mixed 129/B6 Cdkn1b-/- mice 35.  Interestingly, Rb1G/+; Cdkn1b-/- mice also succumb 
to pituitary tumor formation with a delayed latency compared to double mutants and with 
approximately 75% penetrance (Figure 2.2BC).  PCR genotype analysis revealed that 
loss of the wild type copy of Rb1 is ubiquitous in these tumors (Figure 2.2D).  The 
Rb1G/+; Cdkn1b-/- tumor phenotype is highly reminiscent of Rb1+/-; Cdkn1b-/- tumors in 
terms of latency and the requirement for loss of heterozygosity of Rb1 35.  Based on this 
observation, the Rb1G allele appears to be the functional equivalent of an Rb1 null allele 
when combined with p27 deficiency in this context.  These genetic data also imply that  
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Figure 2.2: Cancer susceptibility in Rb1G/G; Cdkn1b-/- mice. 
(A) Picture of young adult double mutant Rb1G/G; Cdkn1b-/- mouse.  (B) Kaplan-Meyer 
analysis of tumor-free survival for mice of the indicated genotypes.  Mice were 
monitored until natural endpoint and those having tumors are shown.  Rb1G/G; Cdkn1b-/-, 
Rb1G/+; Cdkn1b-/- and Rb1+/- are significantly different from one another and from all 
single mutant controls using Log rank test (P<0.05).  (C) Macroscopic images of 
pituitaries of mice from the indicated genotypes at necropsy.  Scale bars are 1cm.  (D) 
Genotyping of tumor and tail DNA isolated from Rb1G/+; Cdkn1b-/- mice demonstrating 
loss of heterozygosity in the tumor tissue.  
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p27 function is required for pRB dependent tumor suppression when pRB is defective for 
E2F binding, and that pRB-E2F control is critical in the absence of p27. 
2.4.3 Compound mutant Rb1G/G; Cdkn1b-/- MEFs enter quiescence 
following serum deprivation.  
The normal development of double mutant animals suggests that pRB-mediated 
repression of E2Fs, as well as deficiency for p27, are dispensable for a variety of cell 
cycle exit decisions that occur as part of a normal mammalian developmental program.  
However, emergence of pituitary adenocarcinomas indicates that this combination is 
important in some context for the mitigation of tumorigenesis.  We therefore sought to 
understand if specific cell cycle control functions are lost in Rb1G/G; Cdkn1b-/- cells.  
Since both pRB and p27 are implicated in quiescence, we assessed their separate and 
combined contributions to serum deprivation-induced arrest 2.  Asynchronously 
proliferating cultures of primary fibroblasts for each of wild type, Rb1G/G, Cdkn1b-/-, 
double mutant Rb1G/G; Cdkn1b-/-, and Rb1-/- were analyzed for their proliferative state by 
BrdU labeling and flow cytometry.  Figure 2.3A shows baseline levels of BrdU 
incorporation for each genotype while actively proliferating, and it shows Rb1G/G; 
Cdkn1b-/-, and Rb1-/- have statistically elevated BrdU incorporation levels.  Cells were 
subsequently washed and transferred to 0.1% serum to induce arrest for 60 hours before 
pulse labeling with BrdU.  While asynchronously cycling double mutant Rb1G/G; Cdkn1b-
/- MEFs exhibit an increase of cells in S-phase while proliferating, these cells could 
restrict S-phase entry following serum deprivation, to a level equivalent to that of wild 
type fibroblasts (Figure 2.3B).  Importantly, the incomplete response in Rb1-/- cells 
indicates that this is a pRB dependent process that Rb1G/G; Cdkn1b-/- cells are capable of  
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Figure 2.3: Compound mutant Rb1G/G; Cdkn1b-/- MEFs enter quiescence. 
(A) Asynchronously growing MEFs were pulsed-labelled with BrdU for two hours 
followed by staining for BrdU incorporation and analysis by flow cytometry.  (B) 
Proliferating cells were serum deprived for 60 hours and pulse-labelled with BrdU for 
two hours followed by staining for BrdU incorporation and flow cytometry.  All error 
bars represent one standard deviation from the mean.  * indicates a significant difference 
from the wild type control using a t-test, p<0.05.  (C) CDK2 kinase activity was 
determined by incubation of immunoprecipitated CDK2 complexes isolated from the 
indicated genotypes of cells under asynchronous growth conditions (AS), or serum 
starved conditions (SS).  Proteins isolated by immunoprecipitation with anti-CDK2 
antibodies (IP) or control (IgG) were mixed with recombinant histone H1 and γ-32P-ATP, 
incubated, and resolved by gel electrophoresis and exposed to a phosphosensitive plate. 
Coomassie staining of the recombinant histone H1 serves as a loading control.  
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executing.  Similarly, analysis of CDK2 activity by IP-kinase assays reveals that single 
mutant Rb1G/G and Cdkn1b-/- cells were also capable of inhibiting CDK2 kinase activity 
(Figure 2.3C), as were double mutant Rb1G/G; Cdkn1b-/- MEFs.  Some residual CDK2 
activity was also observed in the Rb1-/- cells following serum deprivation reflecting the 
defect in G1 arrest observed in Rb1-/- MEFs (Figure 2.3C).  Maintenance of quiescence 
and CDK2 inhibition in double mutant Rb1G/G; Cdkn1b-/- MEFs agrees with the 
developmental milestones observed in Rb1G/G; Cdkn1b-/- mice, as quiescence induction is 
a component of normal development 36. 
2.4.4 Compound mutant Rb1G/G; Cdkn1b-/- cells display defective 
cell cycle control in response to DNA damage.   
The detection of malignancies later in life in Rb1G/G; Cdkn1b-/- mice likely 
indicates that additional mutations occur prior to tumorigenesis.  Therefore, we next 
looked at the ability of single and double mutant Rb1G/G; Cdkn1b-/- MEFs to arrest the 
cell cycle in response to DNA damage, as a defect in this response could facilitate the 
acquisition of new mutations.  We subjected asynchronously proliferating cells to three 
different DNA damaging agents; gamma irradiation (IR), cisplatin, and hydrogen 
peroxide and pulse labelled cells with BrdU 48 hours later.  The percentage of BrdU 
positive cells was then determined by flow cytometry (Figure 2.4A).  With each 
treatment, double mutant Rb1G/G; Cdkn1b-/- and Rb1-/- cells failed to block BrdU 
incorporation.   Interestingly, some single mutants showed modest defects in their 
response to Cisplatin and hydrogen peroxide (Figure 2.4A).  However, analysis of DNA 
content by propidium iodide staining following IR, showed that both double mutant 
Rb1G/G; Cdkn1b-/- and Rb1-/-  
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Figure 2.4: Mutant Rb1G/G; Cdkn1b-/- MEFs display defective cell cycle control in 
response to DNA damage. 
(A) MEFs were treated with the indicated dose of DNA damaging agents.  48 hours later 
cells were pulsed with BrdU, stained and analyzed by flow cytometry.  All error bars 
represent one standard deviation from the mean.  * indicates a significant difference from 
the wild type control using a t-test, P<0.05.  (B) Propidium iodide (PI) staining of MEFs 
treated with 15Gy of ionization radiation showing DNA content of cells.  Red boxes 
outline area of >4N DNA content with the number representing the percentage of cells in 
that box.  (C) Kinase assays were performed using CDK2 kinases isolated from 
asynchronously growing (AS) or following treatment with ionizing radiation (γIR). 
Kinase activity was determined by incubation of immunoprecipitated CDK2 complexes 
with recombinant histone H1 with and γ-32P-ATP followed by gel electrophoresis and 
exposure to a phosphosensitive plate.  Coomassie staining of recombinant histone H1 
serves as a loading control. 
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MEFs exhibit a high proportion of cells with 8N DNA content, implying a strong defect 
in the regulation of DNA replication following damage (Figure 2.4B).  This suggests that 
loss of both pRB-E2F binding and p27 together results in a defective DNA damage 
checkpoint leading to endoreduplication in a manner that is very similar to complete Rb1 
deficiency.  We also tested CDK2 activity from extracts of IR treated cells using an IP-
kinase assay.  Once again, Rb1G/G and Cdkn1b-/- single mutant MEFs could reduce CDK2 
kinase activity down to background levels, whereas double mutant Rb1G/G; Cdkn1b-/- and 
Rb1-/- MEFs were only able to partially restrict CDK2 kinase activity mirroring the result 
seen by BrdU incorporation analysis (Figure 2.4C).  The failure of double mutant 
Rb1G/G; Cdkn1b-/- MEFs to arrest in response to DNA damage provides a possible 
framework to explain the eventual development of pituitary adenocarcinomas in older 
mice.  Therefore, in the context of DNA damage, Rb1G/G; Cdkn1b-/- animals may be 
unable to respond appropriately to the insult, allowing for the development of further 
mutations and the clonal expansion tumorigenic cells. 
2.4.5 Compound mutant Rb1G/G; Cdkn1b-/- fibroblasts undergo 
rapid immortalization in culture.  
We also modeled the acquisition of cancer enabling mutations over time using a 
3T3 immortalization assay to assess the different Rb1 and Cdkn1b mutant genotypes.  By 
passaging primary MEFs in a 3T3 protocol we were able to subject them to long-term 
oxidative stress 37, its resultant DNA damage 37, and determine genotype specific 
responses.  We categorized entry into senescence in this assay as the first passage that 
displays a negative population increase.  Furthermore, we categorized immortalization as 
the first passage where positive population increases resumed and continued 
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uninterrupted for the remainder of the 20 passage experiment.  From this analysis, we 
note that all attempts to immortalize Rb1G/G; Cdkn1b-/- and Rb1-/- MEFs were successful 
(Figure 2.5A), whereas at least half of single mutant or wild type controls entered 
senescence and never resumed proliferation.  All wild type, single mutant, and Rb1G/G; 
Cdkn1b-/- double mutant cells entered senescence as evidenced by negative growth trends 
(Figure 2.5B-F).  In this assay, only Rb1-/- cells spontaneously immortalized without 
entering senescence (Figure 2.5F).  Notably, double mutant Rb1G/G; Cdkn1b-/- cells 
demonstrated a longer period of positive growth compared to single mutants (Figure 
2.5E), and they spent fewer passages in senescence before resuming continual expansion.  
A similar profile of brief arrest before rapid expansion was exhibited by most Rb1-/- cells 
cultures (Figure 2.5F), and this further emphasizes the similarity between the Rb1G/G; 
Cdkn1b-/- and Rb1-/- genotypes in this assay.  This result demonstrates that cells 
containing mutations to abolish pRB-E2F repression and loss of p27, are poised to 
immortalize and this property is consistent with their inability to arrest the cell cycle 
following DNA damage.  
2.4.6 Compound mutant Rb1G/G; Cdkn1b-/- cells in the embryonic 
intermediate pituitary demonstrate radio resistant DNA 
synthesis.   
Given the propensity of Rb1G/G; Cdkn1b-/- mice to develop pituitary tumors as 
demonstrated in this report, and the long history of Rb1 null alleles to predispose mice to 
this tumor type, we sought to assess cell cycle regulation in this tissue.  As the 
intermediate lobe of the pituitary gland gives rise to the adenocarcinomas previously 
reported in Rb1 mutant mice 38,39, we chose to investigate the DNA damage response  
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Figure 2.5: Rb1G/G; Cdkn1b-/- MEFs undergo rapid immortalization in response to 
oxidative stress. 
(A) Percent of cultures that immortalized within 20 passages of 3T3 culture.  
Immortalization was defined as continued positive population growth following a decline 
in cell number at intermediate passages.  (B-F) Population growth of MEFs of the 
indicated genotypes was plotted against passage number.  Cells were plated at a density 
of 1x106 cells per 10 cm plate, and they were re-seeded at the same density every 3 days.  
Population increase was calculated according to the formula: 
(Log10(recovered/seeded))/Log102 and plotted cumulatively over 20 passages, or until no 
viable cells were left in the culture.   
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specifically in these cells.  To analyze acute response to DNA damage in the pituitary, 
embryos at 13.5 days of gestation were used as the peak proliferation of the pituitary 
occurs at this time and postnatal proliferation is largely undetectable 40.  Pregnant 
mothers were exposed to a dose of 10Gy of ionizing radiation four hours prior to 
injection with BrdU and sacrificed two hours later.  Tissue sections of embryos were cut 
to expose the developing pituitary and sections were stained to detect BrdU (Figure 
2.6A).  Wild type, as well as single mutant Rb1G/G and Cdkn1b-/- embryos, displayed a 
robust reduction in BrdU incorporation following DNA damage, as determined by 
counting BrdU positive nuclei in the intermediate lobe of the pituitary (Figure 2.6B).  
Similar to our findings in cell culture both Rb1G/G; Cdkn1b-/- and Rb1-/- embryos did not 
display a significant reduction of BrdU incorporation following irradiation (Figure 2.6B).  
TUNEL staining of parallel sections was performed to quantitate double stranded DNA 
breaks and reveals similar levels of damage among all genotypes (Figure 2.6C).  This 
outcome indicates that the cell cycle arrest defect following DNA damage in double 
mutant Rb1G/G; Cdkn1b-/- cells is evident in both cell culture and in vivo settings, and it 
occurs in the cell population that eventually gives rise to the tumor phenotype seen in 
these mice.  Thus, the regulation of E2Fs by pRB as well as CDK control via p27 are 
each individually dispensable for cell cycle control, simultaneous loss of both leads to an 
insensitivity to DNA damage signalling and a predisposition to cancer. 
2.5 Discussion 
Our findings support the existence of a link between pRB-mediated growth 
control and CDK regulation that is independent of pRB-E2F control of transcription.  The 
similar defect in DNA damage induced growth arrest between Rb1G/G; Cdkn1b-/- and  
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Figure 2.6: Double mutant Rb1G/G Cdkn1b-/- embryonic pituitaries exhibit radio 
resistant DNA synthesis. 
(A) Representative images of E13.5 pituitaries stained for BrdU from control or 
irradiated embryos.  The intermediate lobe of the pituitary is outlined in dashed white 
lines.  (B) The of percentage of BrdU positive cells in the intermediate lobe of the 
pituitary was determined from the indicated genotypes of mice from control or irradiated 
groups.  All error bars represent one standard deviation from the mean.  * indicates a 
significant difference from the wild type control using a t-test, P<0.05.  (C) Tissue 
sections were stained with TUNEL and positive cells within the intermediate lobe of the 
pituitary were quantitated for in the indicated genotypes either with or without 
irradiation.  All error bars represent one standard deviation from the mean and there are 
no significant differences amongst the treated groups.   
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Rb1-/- implies that E2F independent growth control by pRB is dependent on CDK 
regulation by p27.  In addition, we find that defective E2F binding by pRB, or loss of 
p27, are individually tolerated in most arrest assays suggesting their functions are 
somewhat interchangeable.  Lastly, cancer incidence and latency is very similar between 
our Rb1G/+; Cdkn1b-/- mice and previously published Rb1+/-; Cdkn1b-/- mice 35, and this 
suggests that in the absence of p27, the Rb1G allele is approximately equivalent to an Rb1 
null.  Collectively, these data point to a strong interdependence of CDK and E2F 
regulation. 
Previous studies of endogenous pRB function in mice have typically relied on 
knock out alleles.  This approach to mechanistic understanding is constrained by several 
limitations that are overcome in our targeted knock in approach.  First, other pRB family 
members, p107 and p130, increase in expression in pRB’s absence 3,41.  Additionally, 
pRB is reported to interact with over one hundred proteins 42, so complete loss of pRB 
disrupts all of these binding partners, obscuring the roles of individual interactions. For 
these reasons, our Rb1G/G model specifically mitigates these problems allowing us to 
demonstrate a role for pRb-E2F interactions in vivo in tumor suppression.  Surprisingly, 
these studies and our previous report of these mice, reveal that loss of pRB-E2F 
transcriptional repression functions in parallel with p27 in growth control and tumor 
suppression 30.  
We have found that disruption of pRB-E2F interactions act synergistically with 
p27 deletion to bring about a loss of cell cycle control.  The degree of disruption is 
similar to complete pRB knock out and this implies that p27 may lie downstream of pRB 
in an E2F independent growth arrest pathway.  A number of previous reports have 
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identified a link between pRB and p27 as a means of crosstalk between the RB pathway 
and the CDK regulatory pathway 25,26.  pRB has been shown to interact with Skp2 as well 
as the APCCdh1 complex25,26.  These interactions allow pRB to reduce available Skp2 
either through facilitation of Skp2 ubiquitination by APCCdh1 or through Skp2 
sequestration.  Ultimately, these interactions stabilize p27 expression and block CDK 
activity independent of pRB-E2F transcriptional repression.  However, each of these 
reports relies on over expression of pRB as the growth arresting stimulus, leaving in 
question the physiological circumstance where this mechanism works.  We think this 
report offers proof of principle for a pRB-p27 regulatory axis, in addition to showing that 
it functions in DNA damage induced arrest, its inactivation renders mice cancer prone.  
This argues that the pRB-p27 connection is critical to what makes pRB a tumor 
suppressor. 
The interplay between pRB and p27 identified in this study may also provide 
important insight into the utilization of targeted therapies aiming to restore cell cycle 
control.  A number of CDK4/6 inhibitors have been developed in attempts to re-establish 
the G1 checkpoint in cancer cells43-45.  Since CDK4/6 inhibition is known to arrest 
proliferation only when pRB is functional, these inhibitors are generally given to patients 
with pRB positive cancers.  However, pRB status alone does not indicate the 
effectiveness of these treatments 46.  Our analysis of G1 checkpoint control may provide 
some insight into ways to maximize the effectiveness of these treatments.  We suggest 
that reactivation of the pRB pathway by CDK4/6 inhibitors may be more effective in 
cancers with inherently high p27 expression, or whose p27 stabilization pathways remain 
active.  
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Overall, our findings reveal a role for pRB in DNA damage induced cell cycle arrest, 
beyond repression of E2F transcriptional activity that utilizes p27 and CDK inhibition.  
Furthermore, our work suggests a functional context for the regulation of p27 by pRB 
that has been elusive. 
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Chapter 3  
3 Multiple molecular interactions redundantly contribute to 
RB-mediated cell cycle control. 
3.1 Abstract 
The G1-S phase transition is critical to maintaining proliferative control and 
preventing carcinogenesis. The retinoblastoma tumor suppressor (pRB) is a key regulator 
of this step in the cell cycle. Here we use a structure-function approach to evaluate the 
contributions of multiple protein interaction surfaces on pRB towards cell cycle 
regulation. SAOS2 cell cycle arrest assays showed that disruption of three separate 
binding surfaces were necessary to inhibit pRB-mediated cell cycle control. Surprisingly, 
mutation of some interaction surfaces had no effect on their own. Rather, they only 
contributed to cell cycle arrest in the absence of other pRB dependent arrest functions. 
Specifically, our data shows that pRB-E2F interactions are competitive with pRB-CDH1 
interactions, implying that interchangeable growth arrest functions underlie pRB’s ability 
to block proliferation. Additionally, disruption of similar cell cycle control mechanisms 
in genetically modified mutant mice results in ectopic DNA synthesis in the liver. Our 
work demonstrates that pRB utilizes a network of mechanisms to prevent cell cycle entry. 
This has important implications for the use of new CDK4/6 inhibitors that aim to activate 
this proliferative control network. 
3.2 Introduction 
Uninhibited cellular division is a feature of cancer cells. As such, pathways that 
regulate proliferation are typically disrupted in human cancer 1. At a molecular level, the 
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cell division cycle is frequently controlled by decisions made in the G1 phase 2. Once 
through this phase, the cell is committed to DNA replication and ultimately completion of 
cell division. The retinoblastoma gene product (pRB) is a key regulator of the restriction 
point that is responsible for controlling S-phase entry 3. The best known function of pRB 
is the repression of E2F transcription factor activity 4. RB performs this function by 
directly binding the transactivation domain of E2Fs, preventing the recruitment of 
transcriptional activators to influence gene transcription 4. In addition, pRB can recruit 
chromatin regulating enzymes, such as histone deacetylases, to assist in transcriptional 
repression 5. This blocks gene expression that is necessary for DNA synthesis and cell 
cycle entry 2. In the presence of mitogens Cyclin dependent kinases phosphorylate pRB, 
changing its conformation and releasing E2Fs 6. Free E2Fs are then able to stimulate 
transcription and S-phase progression. While this model describes cell cycle entry quite 
accurately, the role for the same molecular interactions between pRB and E2Fs in cell 
cycle exit is less clear as pRB dependent arrest can occur much faster than E2F 
repression 7. 
The minimal interaction domain that mediates stable E2F binding to pRB is the large 
pocket, and this fragment is also the minimal growth suppressing domain 8,9. The large 
pocket is composed of three regions called A, B, and C 3. The A and B domains of pRB 
form the pocket in which the transactivation domain of E2Fs bind 10,11. In addition, pRB 
interacts with a number of chromatin regulators, including HDAC containing complexes, 
through a well conserved interaction site on the B box of pRB known as the LxCxE 
binding cleft 5. This binding site is well defined for its ability to contact the LxCxE motif 
in viral oncoproteins 12. Simultaneous interactions between E2Fs, pRB, and chromatin 
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regulators through LxCxE interactions form the basis of active transcriptional repression 
through E2Fs. The C-terminus of pRB is largely unstructured and serves as a contact 
point for numerous protein interactions 3,13. It is required for stable interaction with E2F-
DP dimers 14, as well as a unique interaction with the marked box domain of E2F1 15. 
Analysis of the large pocket of pRB has contributed to our knowledge of E2Fs in cell 
cycle control. However, there is little to reconcile how multiple competing protein 
interactions through this domain contribute to pRB’s overall influence on cell 
proliferation. 
Genetic ablation of RB causes defects in cell proliferation control in tissues and in 
primary cell culture experiments 16,17. However, early studies of pRB-mediated cell cycle 
regulation exploited the RB null SAOS2 osteosarcoma cell line 8,9,18. RB expression in 
these cells leads to a robust accumulation of 2N DNA content, indicating a G1 arrest 19. 
These studies looked at a variety of mutant versions of pRB in which strong cancer 
derived mutations were functionless, but low penetrance RB mutations retained the 
ability to at least partially restrict cell cycle entry 8,9,20,21. Surprisingly, the low penetrance 
mutation R661W was defective for E2F binding, but retained the ability to inhibit cell 
cycle entry 20-22. More recently, a number of studies have shown that the R661W mutant 
can regulate Cyclin dependent kinase activity through p27, independent of E2F 
transcriptional control 7,23. Importantly, these studies established that the LxCxE binding 
cleft and C domains within the large pocket also mediate interactions with the anaphase 
promoting complex and Skp2 to stabilize p27 expression 7,24. Surprisingly, a unified 
model of how E2F dependent and independent proliferative control mechanisms interact 
has yet to emerge. 
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To understand the importance of different protein interaction points in the RB large 
pocket, targeted mutations to disrupt the LxCxE binding cleft 25-28, the canonical E2F 
binding site 29,30, and pRB’s unique interaction with E2F1 in the C-terminus 31,32, have 
been generated in mice. Analysis of proliferation in cells and tissues from these mutant 
animals suggests that individual protein interactions play context specific roles. For 
example, LxCxE binding cleft mutant mice (called Rb1L, or Rb1NF) are viable with hyper 
proliferation largely limited to mammary ductal epithelium, that is likely due to 
unresponsiveness to growth inhibitory signals from TGF-β 33. Importantly, these mice are 
not spontaneously cancer prone 27,34, and they are capable of blocking E2F transcription 
under several physiological circumstances 35. However, repression of E2F targets is 
diminished following DNA damage, and the ability of these cells to enter senescence is 
compromised 35,36. Furthermore, mutagen treatment induces cancer in these mice under 
conditions where E2F repression fails 26. Disruption of pRB’s unique E2F1 interaction in 
mice (called Rb1S) shows no detectable change in proliferative control in tissues or 
isolated cells 32. Lastly, mutational disruption of pRB-E2F interactions in Rb1G/G mice 
results in cells with accelerated entry into the cell cycle, but normal cell cycle exit 29,30. 
Remarkably, this mutation does not predispose mice to cancer 29, however, disruption of 
this interaction in combination with p27 deficiency deregulates cell cycle arrest functions 
and these mice are highly cancer prone 30. This result is also provocative because the cell 
cycle arrest defects in Rb1G/G; p27 deficient compound mutants aren’t found in either 
single mutant strain alone. These data suggest that pRB dependent cell cycle arrest may 
depend on a complex network of proliferative control signals such that loss of individual 
functions have limited effect on their own. This concept is underscored by the fact that no 
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targeted knock in strain recapitulates the complete proliferative control and cancer 
susceptibility phenotypes of Rb1-/- mice. In this manuscript, we aimed to eliminate 
individual binding surfaces in the pRB large pocket to determine the extent that each 
contributes to cell cycle control alone and in combinations using SAOS2 arrest as a read 
out. Here, we demonstrate that multiple individual binding surfaces in the large pocket 
contribute to pRB-mediated cell cycle control in cell culture, and provide proof of 
principle that this network functions endogenously to regulate DNA replication in the 
liver. 
3.3 Materials and Methods 
3.3.1 GST pulldowns and western blotting 
C33A cells were transfected with either HA-E2F1-3 (along with DP1), myc 
tagged CDH1 or pRB expression plasmids under the control of CMV promoters using 
standard calcium phosphate precipitation techniques. Forty hours after transfection cells 
were washed and collected in GSE buffer (20mM Tris, pH 7.5, 420 mM NaCl, 1.5 mM 
MgCl2, 0.2mM EDTA, 25% glycerol, 5 µg/ml leupeptin, 5 µg/ml aprotinin, 0.1 mM 
Na3VO4, 0.5 mM NaF, and 1 mM DTT) and frozen at -80°C. Cell extracts were 
centrifuged and the supernatant was diluted 2-fold in low salt GSE (20mM Tris, pH 7.5, 
1.5 mM MgCl2, 0.2mM EDTA, 25 mM DTT, 0.1% NP-40) and combined with 
glutathione beads and recombinant fusion proteins. GST-RB large pocket (amino acids 
379-928) and GST-HPV-E7 recombinant proteins were expressed and purified as 
previously described 29. Beads were then washed twice with low salt GSE, boiled in SDS-
sample buffer, resolved by SDS-PAGE, and western blotted. HA-tagged proteins were 
detected using anti-HA 3F10 (Roche), myc-tagged CDH1 was detected using monoclonal 
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antibody 9E11, and pRB was detected with G3-245 (BD Pharmagen). To test pRB 
stability, cells transfected with CMV expressed pRB were treated with 100µg/mL 
cycloheximide for 24 hours. Extracts were prepared in GSE buffer every three hours up 
to 15 hours. Extracts were spun down and western blotted for pRB. 
3.3.2 SAOS2 cell cycle arrest assays 
SAOS2 cells were transfected and harvested as previously described 37. Briefly 
106 cells were plated in 6cm dishes and transfected with 0.15µg of CMV-pRB, 1µg of 
CMV-CD20 and 3.85µg of CMV-β-gal, or 1µg of CMV-CD20 and 4µg of CMV-β-gal as 
a negative control, using X-tremeGENE transfection reagent (Roche). Cells were re-
plated onto 10cm dishes 24 hours after transfection, and harvested 48 hours later. Cells 
were then stained with a fluorescein conjugated anti-CD20 antibody to mark successfully 
transfected cells, as well as with propidium iodide (PI) to determine their DNA content. 
Flow cytometry was then performed to identify the percentage of CD20 positive cells 
with 2N DNA content as a measure of G1. In experiments expressing cell cycle arrest as 
percent change in G1, arrest data was scaled using CMV-pRB and CMV-β-gal as 
standards for maximal increase and unchanged G1 content allowing comparisons 
between different batches of experiments.  
3.3.3 Animal housing, dissection and histology 
All animals were housed and handled as approved by the Canadian Council on 
Animal Care. Mice were sacrificed at 8 weeks of age, dissected, and livers were 
processed for downstream applications. For histology, livers were fixed in formalin for 
72 hours followed by 72 hours in PBS before being stored in 70% ethanol. Livers were 
then embedded in paraffin and five micron sections were cut and stained with 
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Hematoxylin and Eosin. Images were captured on a Zeiss Axioskop 40 microscope and 
Spot Flex camera, and nuclear area in the livers was calculated using EyeImage software 
(Empix Imaging, Mississauga, Ontario, Canada).  
3.3.4 Ploidy analysis of adult livers 
A small piece of frozen liver was added to buffer A (25mM Tris pH 7.5, 50mM 
KCl, 2mM MgCl2, 1mM EDTA, 1mM PMSF). Tissue was ground on ice with a 
mechanical tissue grinder. Tissue was then homogenized using a 1mL dounce 
homogenizer and tight pestle. Nuclei were centrifuged at 12000xg, then washed in buffer 
A and centrifuged. The pellet was then resuspended in Propidium Iodide solution 
(0.5mg/mL PI, 0.1% NP-40, 0.1% sodium citrate, 40µg/mL RNase A in PBS). Samples 
were then analyzed by flow cytometry using standard methods to quantitate DNA 
content. 
3.3.5 RNA isolation and E2F target gene quantification. 
RNA from livers was isolated using an RNeasy fibrous tissue kit (Invitrogen).  
Expression levels of the E2F target genes, Pcna, Ccne1 (Cyclin E1), Ccna2 (Cyclin A2), 
Tyms (thymidylate synthase), Mcm3, and Rbl1 (p107), were determined using the 
Quantigene Plex 2.0 reagent system from Affymetrix (Santa Clara, CA) and a 
BioPlex200 multiplex analysis system as previously reported 38. Expression levels were 
normalized to the expression of β-actin. 
3.3.6 BrdU staining of tissue sections.  
To analyze DNA replication, mice were injected with 200L of 16µg/mL BrdU 
(Sigma) in their peritoneal cavity 2 hours before sacrifice. Livers were then isolated, 
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fixed in formalin, embedded, and sectioned according as above. Sections were 
deparaffinized and rehydrated using a series of xylene and ethanol washes. The sections 
were brought to a boil in sodium citrate buffer and then maintained at 95°C for 10 min. 
The cooled sections were rinsed in water three times for 5 minutes, and then rinsed in 
PBS for 5 minutes. The sections were blocked in phosphate buffered saline (PBS) 
supplemented with 2.5% horse serum and 0.3% Triton X-100 for 1 hour. The sections 
were then incubated with anti-BrdU antibodies (BD-Biosciences) in blocking buffer 
overnight at 4°C and rinsed in PBS three times for 5 minutes each time. The slides were 
incubated with horse anti-mouse immunoglobulin G-fluorescein isothiocyanate (Vector) 
for 1h and rinsed in PBS. The slides were then mounted with Vectashield plus DAPI 
(Vector). Fluorescent images were captured on a Zeiss Axioskop40 microscope and Spot 
Flex camera and colored using EyeImage software (Empix Imaging, Mississauga, 
Ontario, Canada), or a similar system. 
3.4 Results 
3.4.1 A cell culture assay demonstrates molecular redundancy of 
RB functions in proliferative control.  
Tumor suppression by the retinoblastoma protein has typically been associated 
with its ability to block cell cycle progression and repress E2F transcription factors 4. 
However, defective E2F binding by pRB has been shown to have modest effects on 
proliferative control in SAOS2 cell culture experiments 15,20-22, and gene targeted mouse 
models 29,30. In an attempt to describe the molecular interactions necessary for pRB-
mediated cell cycle arrest we investigated forms of pRB that were individually mutated at 
each of three distinct binding surfaces in the large pocket; the general E2F binding site  
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Figure 3.1: Interaction domains located in the large pocket of pRB and substitutions 
used in this study. 
 
(A) Linear diagrams of open reading frames for the indicated proteins highlighting the 
regions that mediate interactions with pRB. Note pRB can bind E2F1-4 through the 
transactivation domain in the C-terminus of E2Fs known as the ‘general’ interaction. 
Alternatively, pRB can also bind the marked box domain of E2F1 through its C-terminal 
domain, termed the pRB-E2F1 ‘specific’ interaction. (B) Locations of point mutations 
within the pRB open reading frame used in this study. RBG refers to mutations that 
disrupt the E2F general interaction, RBS is a mutation that disrupts the E2F1 specific 
interaction. RBC and RBL both disrupt interactions through the LxCxE binding cleft. All 
codon numbers correspond to the human sequence. The large pocket domain is amino 
acids 379-928. (C) Diagram depicting the cell cycle control mechanisms that can be 
influenced by the 3 pRB binding surface mutations used in this study.  
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(RBG), the E2F1 specific site (RBS), and the LxCxE binding cleft (using either the RBL or 
RBC mutations). Figure 3.1A diagrams pRB protein interactions and shows the relevant 
regions in each open reading frame that participate. Amino acid substitutions that are 
demonstrated to disrupt these contacts are shown in Figure 3.1b 24,37,39,40, along with 
single letter nomenclature for each allele (e.g. RBG). Lastly, the types of interactions 
between pRB and E2Fs, or LxCxE motif proteins, are illustrated with the alleles that 
disrupt them individually shown on the right, and the intended effect of a combined 
mutant allele on the left (Figure 3.1C).  
GST-tagged versions of the pRB large pocket (GST-RBLP, pRB amino acids 
379-928) containing the 3 mutations described above, as well as the triple mutant, were 
produced in bacteria. GST pulldowns were performed to test interaction defects predicted 
to occur in these mutants (Figure 3.2A). RB deficient C33A lysates derived from 
transfections with the indicated E2Fs, or CDH1 were produced and used in pulldown 
experiments. As expected the RBG mutation disrupts binding of the activator E2Fs, E2F2 
and E2F3. RBL disrupts the LxCxE binding cleft and is defective for binding the 
anaphase promoting complex targeting subunit CDH1. Finally, since E2F1 can associate 
with pRB through two qualitatively different interactions, the general site and the specific 
site, binding is only lost following mutation of both sites in the triple mutant RBGSL. Full 
length pRB constructs containing these mutations were then transfected into SAOS2 cells 
to determine their effectiveness in causing a G1 cell cycle accumulation. As previously 
shown, expression of wild-type pRB in SAOS2 cells lead to a build up of cells in G1 as 
determined by propidium iodide staining and flow cytometry (Figure 3.2B)19. Expression 
of the mutant constructs of pRB had various levels of effectiveness for  
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Figure 3.2: Multiple point mutations are needed to overcome RB-mediated cell cycle 
arrest. 
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Figure 3.2: Multiple point mutations are needed to overcome RB-mediated cell cycle 
arrest. 
(A) GST-tagged RB large pocket proteins corresponding to the RBG, RBS, RBL, and 
RBGSL mutant versions of pRB were produced and purified. These GST-fusions were 
incubated with C33A extracts transfected with the indicated expression constructs. Bound 
proteins were isolated by precipitation and identified by western blotting. (B) Constructs 
containing full-length RB harboring the indicated mutations under the control of a CMV 
promoter were transfected into SAOS2 cells along with a CD20 reporter. Cells were then 
stained with propidium iodide and the percentage of cells in G1 were determined by 
DNA content of CD20 positive cells. Bars indicate the mean of three separate 
experiments, and error bars indicate one standard deviation from the mean. Letters 
indicate groups that are significantly different from one another (ANOVA, Tukey test, 
p<0.05). (C) Full length CMV-RB constructs were transfected into C33A cells and 
extracts were incubated with recombinant HPV-E7. Bound proteins were isolated by 
precipitation and western blotted to detect pRB. (D) Full length RBWT and RBGSC were 
transfected into C33A cells prior to cycloheximide treatment (CHX). Extracts were 
prepared over a 15 hour time course and stability was monitored by Western blotting. (E) 
Constructs containing full-length RB harboring the various mutations, or combinations of 
mutations, under the control of a CMV promoter were transfected into SAOS2 cells along 
with a CD20 reporter. Cells were then stained with propidium iodide and the percentage 
of cells in G1 were determined by DNA content of CD20 positive cells. Bars indicate the 
mean of three separate experiments, and error bars indicate one standard deviation from 
the mean. (F) Transfections and cell cycle analysis were performed as in B and E, except 
the increase in G1 cells is shown as Change in % G1 (relative to β-Gal control). Letters 
indicate groups that are significantly different from one another (ANOVA, Tukey test, 
p<0.05). 
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inducing a G1 cell cycle arrest (Figure 3.2B). Notably, the RBS mutation showed a 
similar ability to block proliferation as wild-type RB (Figure 3.2B). By contrast, 
disruption of the general binding pocket in the RBG mutant, or disruption of the LxCxE 
binding cleft (RBL) resulted in a significant, but partial decrease in the percentage of cells 
in the G1 phase of the cell cycle (Figure 3.2B). Importantly, no individual mutation can 
completely disrupt RB function. However, when all three mutations were combined into 
one pRB molecule (RBGSL), the ability of pRBGSL to induce a G1 arrest was not 
statistically different from that of the β-Gal negative control (Figure 3.2B). As disruption 
of the various interactions lead to an inability of pRB to bind to any of its LxCxE or E2F 
interactors, we next aimed to confirm that combination mutations led to disruption of 
these binding surfaces, as opposed to simply disrupting pRB structure or stability. To 
address this possibility, we used the RBC mutation that retains the ability to associate 
with HPV-E7, but has previously been shown to be defective for its interaction with 
CDH1 24,37,39,40. Figure 3.2c demonstrates that both the RBC, and an RBGSC combination 
could maintain RB-E7 interaction, suggesting this mutant combination retains it structure. 
Furthermore, the stability of the RBGSC mutation was determined by expressing both 
RBWT and RBGSC in C33A cells. Cells were then treated with cycloheximide and protein 
was isolated over a period of 15 hours. Western blots confirmed that RBWT and RBGSC 
have equal stability, further suggesting that these substitutions do not result in the 
misfolding and hence pleiotropic loss of pRB function (Figure 3.2D). Finally, SAOS2 
cell cycle arrest assays were performed using the RBC mutant alone or in double and 
triple combinations (RBGC or RBGSC). As with the RBGSL mutant, the triple mutant 
combination RBGSC was unable to increase the proportion of G1 cells beyond that of β-
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Gal controls (Figure 3.2E). In addition, SAOS2 cell cycle arrest following transfection 
with the RBGC and RBGS double mutants diminished the ability to induce a G1 cell cycle 
arrest beyond any single mutant, but was less detrimental than the RBGSC combination 
(Figure 3.2F). These results demonstrate that pRB’s activity in this arrest assay can be 
defined through loss of individual protein interactions.  
The combination of RBG and RBL mutations in RBGSL is more severe than either 
alone (Figure 3.2B). It is difficult to envision LxCxE interaction defects enhancing loss 
of function of pRB-E2F binding defects through transcriptional control since the RBG 
mutation already disrupts recruitment to E2F promoters 29,30. For this reason, we 
investigated non-E2F dependent mechanisms that could be lost because of the RBL 
mutation such as binding to CDH1. To investigate how E2F and CDH1 dependent arrest 
mechanisms may relate to one another, we tested pRB’s ability to interact with each 
simultaneously. For this experiment, we mixed C33A extracts containing myc-tagged 
CDH1 with increasing amounts of HA-E2F3/DP1 extracts and tested their ability to bind 
to GST-RBLP in pulldown experiments (Figure 3.3). This experiment reveals that 
increasing quantities of HA-E2F3/DP1 prevent myc-CDH1 from binding to GST-RBLP 
(Figure 3.3, left side). Disruption of E2F3 binding to pRB using a GST-RBLPG mutant 
prevents competition with myc-CDH1 for binding to pRB. This experiment suggests that 
pRB is unable to engage E2F3 and CDH1 dependent functions simultaneously, 
suggesting that these functions are interchangeable. This mirrors findings from recent in 
vivo approaches to pRB dependent cell cycle control 30, and this will be explored further 
in the discussion.  
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Figure 3.3: Competition between E2Fs and CDH1 for pRB binding. 
Purified GST-RBLP or an -RBLPG mutant was incubated with constant levels of myc-
CDH1, and increasing quantities of HA-tagged E2F3/DP1 from transfected lysates.  
GST-pulldowns were performed and associated levels of myc-CDH1 and HA-E2F3/DP1 
were determined by western blotting. Western blots using anti-pRB antibodies show the 
levels of GST-RBLP proteins precipitated in each experiment. 
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3.4.2 A compound mutant mouse model demonstrates molecular 
redundancy in RB control of DNA replication.  
Mutation of all three binding surfaces in the RB large pocket was required to 
maximally impair RB-mediated cell cycle control (Figure 3.2BE). This finding, 
combined with the fact that individual mutations for each of these binding sites in gene 
targeted mice did not phenocopy the Rb1-/- proliferative control defects in primary cell 
culture, suggests that the function of pRB in cell cycle control may be composed of 
several distinct mechanisms 28,29,32. To approximate the dysfunction of the RBGSL 
mutation in vivo as diagrammed in Figure 3.1C, we combined our previously published 
Rb1G/G animals that disrupts pRB-E2F interactions with p27 null mice (Cdkn1b-/-) to 
eliminate its influence on cell cycle control 30. In addition, we crossed these mice into an 
E2F1 null background to eliminate any effect on cell cycle regulation by the pRB-E2F1 
specific interaction. This combination of mutations Rb1G/G; Cdkn1b-/-; E2f1-/-, represents 
one potential scenario of the effects of the RBGSL mutation in vivo on cell cycle control. 
Interestingly, Rb1G/G; Cdkn1b-/-; E2f1-/- (triple mutant) animals are viable and occur at 
normal Mendelian ratios (Table 3.1). 
Since triple mutant mice did not phenocopy the embryonic lethality seen in Rb1-/- 
animals we next sought to determine if any tissues display loss of cell cycle control 41. 
Previously, Mayhew et al. showed that tissue specific knockout of pRB in the murine 
liver resulted in the up regulation of E2F target genes and ectopic DNA replication, 
endoreduplication, and accumulation of nuclei with elevated ploidy 42. Since hepatocytes 
often endoreduplicate it is possible to detect the accumulation of misregulated DNA  
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Table 3.1: Frequency of compound mutant mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The indicated genotypes of mice were crossed and all resulting progeny were genotyped. 
The number of live animals obtained at two weeks of age is indicated for each genotype 
and the expected number based on Mendelian inheritance is indicated in brackets. * 
Indicates significance as determined by chi-squared test.  
        E2f1-/-; Rb1G /+; Cdkn1b+/-  
X     E2f1-/-; Rb1G /+; Cdkn1b+/-  
Genotype P14 
E2f1-/-; Rb1+/+; Cdkn1b+/+ 8 (13) 
E2f1-/-; Rb1+/+; Cdkn1b+/- 29 (26) 
E2f1-/-; Rb1+/+; Cdkn1b-/- 12 (13) 
E2f1-/-; Rb1G/+; Cdkn1b+/+ 29 (26) 
E2f1-/-; Rb1G/+; Cdkn1b+/- 64 (52) 
E2f1-/-; Rb1G/+; Cdkn1b-/- 9* (26) 
E2f1-/-; Rb1G/G; Cdkn1b+/+ 12 (13) 
E2f1-/-; Rb1G/G; Cdkn1b+/- 35 (26) 
E2f1-/-; Rb1G/G; Cdkn1b-/- 10 (13) 
Total  208 
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replication over time 35. We therefore, aimed to analyze aspects of cell cycle control in 
the livers of Rb1G/G; Cdkn1b-/-; E2f1-/- animals to determine if these mutations were 
capable of disrupting pRB control of DNA replication. H&E staining of livers revealed 
that hepatocyte triple mutant adult livers had enlarged nuclei that on average were three 
times larger that wild-type and Rb1G/G; Cdkn1b-/- double mutant animals as well as twice 
as large as Rb1G/G and Rb1G/G; E2f1-/- nuclei (Figure 3.4AB). We also quantitated the 
density of hepatocytes per microscopic field of view and did not see significant 
differences between genotypes (Figure 3.4C). Since nuclear area in liver histology 
correlates with DNA content 43, this suggested elevated levels of endoreduplication in 
Rb1G/G; Cdkn1b-/-; E2f1-/- triple mutant livers. To test whether our triple mutant had 
elevated ploidy in their hepatocytes, nuclei were extracted from livers of Rb1+/+, Rb1G/G, 
and Rb1G/G; Cdkn1b-/-; E2f1-/- mice, stained with propidium iodine, and analyzed by flow 
cytometry for DNA content. Consistent with previous results we found that Rb1+/+ livers 
at 8 weeks of age display very low levels of 8N DNA content, however triple mutant 
livers displayed a significant increase in the level of 8N DNA at this time point (Figure 
3.4C), that is similar to what is reported when Rb1 is conditionally deleted in this organ 
42. This increase in nuclear size and subsequent DNA content indicates that triple mutant 
livers undergo endoreduplication. While this is a normal phenotype for liver cells over 
time, this suggests that the loss of these three regulatory elements controlled by pRB 
results in earlier endoreduplication, potentially due to a loss of cell cycle control.  
We next wanted to determine the effect of our combined mutations on the 
regulation of pRB functions related to cell cycle control. To accomplish this, RNA was 
isolated from adult livers to analyze the expression of E2F target gene transcription.  
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Figure 3.4: Ectopic DNA-replication in Rb1G/G; Cdkn1b-/-; E2f1-/- compound mutant 
mice. 
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Figure 3.4: Ectopic DNA-replication in Rb1G/G; Cdkn1b-/-; E2f1-/- compound mutant 
mice. 
 
(A) H&E staining of liver sections from eight-week old wild type, Rb1G/G, double mutant 
Rb1G/G; Cdkn1b-/-, and Rb1G/G; E2f1-/- mice, as well as Rb1G/G; Cdkn1b-/-; E2f1-/- triple 
mutant animals.  The scale bars represent 20 μm. (B) Nuclear size from the images in A 
was determined and the mean size is indicated.  Measurements were made from at least 
50 nuclei, a, b, c represents statistically different groups as determined by ANOVA 
followed by Tukey’s test (p<0.05). (C) Total number of hepatocytes per 20X field of 
view was averaged from the indicated genotypes. No statistical differences were observed 
by AVONA followed by Tukey’s test (p<0.05) (D) Nuclei were extracted from livers, 
stained with propidium iodide, and analyzed for DNA content by flow cytometry. (E) 
The relative expression level of six E2F cell cycle target genes from wild type, Rb1G/G, 
and Rb1G/G; Cdkn1b-/-; E2f1-/- was determined from RNA extracted from 8-week-old 
livers. (F) Eight-week-old mice were pulse labeled with BrdU two hours prior to sacrifice 
and livers were sectioned and stained for BrdU. The percentage of BrdU positive nuclei 
was determined.  At least 500 nuclei were counted per mouse. All bar graphs represent at 
least 3 individual experiments, and error bars indicate one standard deviation from the 
mean. An asterisk represents a statistically significant difference from the wild type 
control (t-test, P<0.05).  
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Consistent with our previous findings, E2F target gene expression in Rb1G/G animals is 
higher than wild-type levels 29. Interestingly, triple mutant livers show high expression of 
some of these target genes (Figure 3.4E). However, in some cases, E2F target gene 
expression is unchanged from wild type and this will be discussed later. To directly 
measure proliferation in livers, 8-week-old animals were injected with BrdU to label 
nuclei with actively replicating DNA. Livers were dissected, sectioned and stained for 
BrdU incorporation. This analysis showed that while both Rb1G/G and Rb1G/G; Cdkn1b-/-; 
E2f1-/- livers display increases in the expression of E2F target genes only triple mutant 
livers displayed increased BrdU incorporation (Figure 3.4EF). Taken together with the 
increased nuclear area and 8N DNA content in triple mutant livers, these results suggest 
that by mutating the general binding site of pRB, and eliminating both p27 and E2F1, we 
have recapitulated the DNA replication defects associated with conditional deletion of 
Rb1 in adult livers. These in vivo results also mirror the effects seen in the SAOS2 arrest 
assays that suggest that no individual protein interaction with pRB accounts for its 
activity in cell cycle control. Instead, these data indicate that pRB likely sits in the center 
of a network of regulators that control DNA replication and cell division. 
3.5 Discussion 
In this manuscript, we aimed to further the understanding of pRB-mediated cell 
cycle control by disrupting pRB-binding interactions in the large pocket to quantitatively 
account for its arrest mechanisms. This structure-function analysis demonstrated that to 
disrupt the vast majority of pRB’s cell cycle arrest activity, three different binding 
surfaces needed to be altered. Surprisingly, no single interaction site was indispensable 
and disruption of some interaction sites had little effect on their own. We used a genetic 
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cross to cripple these three aspects of pRB function endogenously and the combination 
caused ectopic DNA replication in the liver. This suggests that pRB may interchangeably 
use different protein interactions to influence cell cycle advancement. Insights and 
caveats of our study are discussed below. 
It is difficult to predict the proliferative control defects of an Rb1 deficient mouse 
beyond neonatal lethality due to muscle atrophy 44. Interestingly, chimeric mice 
composed of a mixture of wild type and Rb1-/- cells are viable and demonstrate normal 
tissue cellularity, even in organs where Rb1-/- cells contribute extensively 17. This study 
reveals that livers containing Rb1-/- hepatocytes display random, large nuclei, similar to 
our findings in triple mutant livers 17. In addition, conditional ablation of Rb1 in the livers 
of adult mice is reported to cause unscheduled DNA replication 42. The increase in DNA 
copy number and BrdU incorporation was indicative of a loss of regulation of DNA 
synthesis 42. In an effort to model the effects of the RBGSL mutant in vivo, we combined 
Rb1G/G animals with p27 and E2F1 deficiency to produce triple mutant animals (Rb1G/G; 
Cdkn1b-/-; E2f1-/-). This combination of mutations lead to a very similar DNA replication 
phenotype in the liver as complete Rb1 deletion. While this is a similar phenotype as 
conditional deletion of Rb1, by no means does our study elucidate all that pRB or E2Fs 
do to block the cell cycle in this or other tissues. We anticipate that viability of triple 
mutant mice suggests additional pRB dependent cell cycle arrest mechanisms likely 
remain functional in these animals. Another important consideration in our efforts to 
model the RBGSL mutant in vivo is that deleting Cdkn1b and E2f1 is not the equivalent to 
disrupting the binding sites on pRB that regulate them, as these interaction sites may have 
additional regulatory effects beyond the downstream targets we have chosen. In addition, 
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loss of E2F1 could diminish cell proliferation even when entry into S-phase is 
deregulated and this could further complicate the interpretation of our analysis of triple 
mutant livers. Importantly, others have demonstrated that the choice between 
proliferation and endoreduplication in hepatocytes is determined by opposing effects of 
activator E2Fs (such as E2F1) and the E2F7 and E2F8 repressors 45,46. It is difficult to 
predict how the triple mutant combination used here would affect the regulation of this 
network of genes to cause a switch to endoreduplication. Future experiments using Rb1 
gene targeted mice carrying a combination of G, S, or L mutations in a single allele will 
help resolve some of these complexities.  
We observed that some individual mutations contributed modestly to proliferative 
control alone, and more strongly when in combination with other substitutions. We 
suggest that this may be due in part to the competition between different cell cycle 
control mechanisms for access to pRB. For example, we demonstrate that E2F3 and 
CDH1 can compete for the opportunity to interact with pRB, and this is consistent with 
previous reports of E2F1 and CDH1 competing for pRB 47. We suggest that CDH1 
interactions with pRB are fundamentally different than other pRB interactors that contact 
the LXCXE binding site simultaneously with E2Fs 3. Another way to consider 
redundancy of function through endogenous pRB is a gene targeted mouse model bearing 
an R654W mutation (the murine equivalent of the low penetrance human mutation 
R661W). This mutation not only disrupts E2F binding, it also compromised interactions 
at the LXCXE cleft 20, potentially illustrating the effects of multiple mutations in a single 
pRB molecule akin to RBGC in our studies. Fibroblast cells from these mice possess many 
features of deregulated proliferation seen in Rb1-/- cells and this mutation is lethal during 
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embryogenesis 48. However, some aspects of pRB’s role in differentiation and its ability 
to respond to senescence inducing stimuli and resistance to tumor formation are retained 
48,49, suggesting that simultaneous deficiency by pRB for multiple interactions can reveal 
a more dramatic phenotype than loss of single interactions. This conclusion is further 
supported by deregulated cell cycle control and cancer incidence in Rb1G/G; Cdkn1b-/- 
mice50, suggesting loss of multiple pRB dependent proliferative control pathways can be 
dramatically different than loss of a single pathway. 
Consistent with multiple interactions needing to be compromised to abrogate cell 
cycle arrest by pRB, we also note that some mutations tested in this study, such as the 
M851A, V852A changes (RBS), have no effect on proliferative control in the SAOS2 
assay on their own. We suggest that it may represent a latent proliferative control 
mechanism used by pRB, and there may be others. A long standing puzzle in the RB field 
has been the existence of proliferative control mechanisms that are mediated by the N-
terminus of pRB, outside of the original growth suppressing large pocket domain 51-53. 
Recent work has suggested that the N-terminus also plays a role in regulating DNA 
replication 53.  This may explain the phenotypic difference in proliferative control 
between Rb1-/- animals and that of triple mutant Rb1G/G; Cdkn1b-/-; E2f1-/- animals as the 
N-terminus is unaffected by our three mutations. There may also be redundancy between 
N-terminal and large pocket growth arrest mechanisms. Provocatively, there are also low 
penetrance mutations in human RB1 that target this region of pRB; further suggesting the 
N-terminus contributes to pRB’s proliferative control and tumor suppressor functions 54. 
We think that interchangeability of different pRB functions in proliferative control best 
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explains our data and also encompasses additional work in the field that has previously 
been difficult to reconcile.  
RB dependent proliferative control is functionally inactivated in the vast majority 
of cancers. This study furthers our understanding of the importance of the various 
interaction surfaces of pRB and their roles in cell cycle control. In addition, CDK4/6 
inhibitors have recently been developed to reactivate the RB-pathway in cancer 55-57. 
Understanding the molecular interactions made by pRB and how they influence cell cycle 
control and tumor suppression is crucial to the proper implementation of these drugs. We 
expect that the mutational status of both pRB, as well as its regulation of p27 and E2Fs, 
will play a critical role in the effectiveness of these drugs. We suggest that patients whose 
tumor cells have pRB activatable p27 will benefit most from CDK4/6 inhibitors.  
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Chapter 4  
4 Tumor-suppressive functions of pRB independent of 
E2F repression 
4.1 Introduction 
The maintenance of cell cycle control is crucial to the prevention of tumorigenesis1. 
Cell cycle progression is regulated through a number of checkpoints that ensure proper 
signalling is present instructing the cell to grow and divide1. Cancer develops when these 
mechanisms are perturbed resulting in cells that continue to cycle regardless of the 
presence or absence of growth stimuli1. To ensure that cells only replicate their genome 
once per cell cycle the primary regulation of cellular division occurs prior to the onset of 
DNA synthesis2. The transition from Gap 1 (G1) phase to that of synthesis (S) phase is 
therefore also known as the restriction point2. Several intra- and extracellular signals 
contribute to cell cycle decisions. These signals influence two main complexes which 
control the restriction point and ultimately cell cycle entry, pRB and Cyclin E/CDK23,4. 
These two proteins work in opposition to one another with pRB restricting cell cycle 
entry and Cyclin E/CDK2 promoting division4. 
Overall, cell cycle entry is determined by the total amount of Cyclin E/CDK2 activity 
which is responsible for phosphorylating a vast network of transcription factors and is 
critical in the firing of replication origins initiating the process of DNA replication5. Both 
Cyclin E/CDK2 and pRB can also influence the activity of each other ensuring that the 
cell doesn’t undergo division prematurely or indecisively5,6. This interplay is primarily 
due to the ability of Cyclin E/CDK2 to hyperphosphorylate pRB resulting in a 
conformational change and subsequent release of the E2F transcription factors4. The lack 
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of pRB binding to E2Fs leads to the upregulation of the E2F transcriptional program 
which contains several genes involved in S-phase progression, one of which is CCNE1 
encoding Cyclin E6. This then increases the overall level of Cyclin E/CDK2 complexes 
resulting in further phosphorylation of pRB4,5. This feed forward loop ensures that once 
the cell is appropriately stimulated to divide the cell is committed to completing the cell 
cycle5,7. In addition to regulating E2F-mediated transcription, we and others have 
characterized an additional axis of pRB-mediated cell cycle control through the 
stabilization of p278-10. 
The two main functions which help to regulate cell cycle progression, E2F repression 
and p27 stabilization are mediated through two independent binding surfaces4,8. The first 
and most well known is through the direct repression of E2F transcription factor activity, 
facilitated through the pocket domain on pRB4. This interaction prevents the transcription 
of genes required for DNA synthesis and cell cycle progression4. The second method of 
pRB-mediated cell cycle control, p27 stabilization, is dependent on Cdh1 binding to pRB 
through the LxCxE binding cleft (Chapter 3)9. This interaction enhances the ability of 
APCCdh1 to degrade its target Skp2 resulting in the stabilization of p279,10. Stabilization of 
p27 leads to the inhibition of Cyclin/CDK (Cyclin dependent kinase) complexes 
preventing S-phase entry and DNA synthesis5 
Given the importance of pRB in regulating both E2F target gene expression and CDK 
activity, pRB plays a critical role in maintaining the G1 restriction point4,9,10. As 
disruption of the restriction point is a necessary step in carcinogenesis, it is unsurprising 
that the pRB pathway is often the target of mutations in human cancers11. Significantly, 
the vast majority of mutations that disrupt pRB function are often upstream of pRB 
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through the deletion of p16 or the amplification of Cyclin D leading to the 
hyperphosphorylation of pRB11. The hyperphosphorylation of pRB simulates active 
growth signalling resulting in E2F target gene expression and cell cycle entry.  
However, recent studies have suggested that this is not the whole story10,12,13. In 
particular, the Rb1G/G mouse model developed by Cecchini et al., in which pRb was 
mutated to disrupt pRb-E2F binding, shows no overt phenotypes12. This finding 
demonstrates that the ability of pRB to repress E2Fs is dispensable for cell cycle control 
and tumor-suppression12. In support of this hypothesis we have also shown that at least 3 
different binding surfaces play a role in regulating cell cycle control (Chapter 3). 
Two critical proteins which influence pRB and the cell cycle are Kras and p5314,15. 
These pathways are also typically mutated in human cancers3,16. These two proteins work 
in opposition to one another with Kras being activated through growth factor stimulation, 
resulting in increased Cyclin/CDK activity and inactivation of pRB14,15. By contrast p53, 
which is stimulated by DNA damage, increases the transcription of the Cyclin dependent 
kinase inhibitor p2115. The increased level of p21 inhibits the function of Cyclin/CDKs 
thereby allowing pRB to remain hypophosphorylated and active, restricting cell cycle 
progression15. The collective input from these signals along with others determines the 
phosphorylation status of pRB, its subsequent activity, and overall cell cycle 
progression4,14,15.  
As we have previously shown, loss of E2F repression by pRB leads to tumorigenesis 
in the absence of p27 (Chapter 2)8. To determine the importance of E2F repression by 
pRB in tumorigenesis, we performed a series of genetic experiments where our Rb1G/G 
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mice were combined with oncogenic KrasG12D as well as inactivation of the p53 pathway 
through deletion of either p53 or p21. These crosses demonstrated that pRB-E2F 
interactions are inconsequential in the face of constitutive proliferative signalling through 
oncogenic Kras activation. However, regulation of E2Fs by pRB does influence tumor-
free survival in conjugation with Trp53 deletion. Finally, we found that deletion of p21 in 
the Rb1G/G background did not result in tumor formation despite having a defective DNA 
damage response. This is of particular interest as an ineffective DNA damage response is 
likely partially responsible for the pituitary tumor formation we observed in 
Rb1G/G;Cdkn1b-/- animals in chapter 28. 
4.2 Materials and Methods 
4.2.1 Phenotypic analysis of animals.  
LSL-KrasG12D mice (B6.129S4-Krastm4Tyj/J) mice and UBC-Cre-ERT2 (B6.Cg-
Tg(UBC-cre/ERT2)1Ejb/2J) were combined with our Rb1G/G mouse model to produce 
both control KrasG12D; Cre-ERT2 animals and experimental Rb1G/G; KrasG12D; Cre-ERT2 
animals12,17,18. Animals were then injected with 75mg/kg tamoxifen at 8 weeks of age 
resulting in sporadic KrasG12D expression throughout the body. Animals were then 
monitored for tumor formation and sacrificed at animal protocol endpoints. Survival data 
were subjected to Kaplan-Meier analysis, and significant differences were compared 
using a log rank test. 
Trp53-/- mice (129-Trp53tm1Tyj/J), and Cdkn1a-/- mice (B6.129S6(Cg)-
Cdkn1atm1Led/J) have been described previously and were obtained from Jackson 
Laboratory19,20. These two strains were combined with our previously described Rb1G/G 
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mouse model and were genotyped as previously described12,19,20. Mice were monitored 
for tumor development and sacrificed at animal protocol endpoints. Survival data were 
subjected to Kaplan-Meier analysis, and significant differences were compared using a 
log rank test. All animals were housed and handled as approved by the Canadian Council 
on Animal Care.  
4.2.2 Histological analysis of tumors 
Following euthanasia, mice were subject to necropsy where tissues of interest 
were fixed in formaldehyde for 72 hours. Tissues were then washed twice in PBS before 
storage in 70% ethanol. Tissues were then embedded in paraffin, 5µm sections were cut 
and stained with hematoxylin and eosin (H&E). Images were obtained using a Zeiss 
Axioskop 40 microscope and Spot Flex camera and software (Mississauga, Ontario, 
Canada). 
4.2.3 Proliferation analysis 
Mouse embryonic fibroblasts (MEFs) were derived from E13.5 embryos of the 
indicated genotypes. Cells were cultured using standard methods in Dulbecco’s modified 
Eagle’s medium containing 10% fetal bovine serum (FBS) 2mM glutamine, 50U/ml 
penicillin and 50µg/ml streptomycin. Cells were treated with 15 Gy of ionizing radiation 
as previously described8. 48 hours after treatment cells were labeled with BrdU for 2 
hours. Cell cycle analysis was then carried out as previously discribed21. 
4.2.4 Expression analysis of pluripotency factors 
MEFs of the indicated genotypes were cultured in Dulbecco’s modified Eagle’s 
medium containing 10% fetal bovine serum (FBS) 2mM glutamine, 50U/ml penicillin 
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and 50µg/ml streptomycin and RNA was isolated using Trizol reagent according to 
manufactures instructions and previously published protocols12. Expression levels of 
Sox2, Klf4, Oct4, and Nanog were analyzed by qRT-PCR and normalized to GAPDH 
using iQ Sybr-green Super mix (Bio-Rad) and the following primer sets: Sox2 Fwd 
(5`ACAGATGCAACCGATGCACC 3`), Sox2 Rev (5`TGGAGTTGTACTGCAGGGCG 
3`), Oct4 Fwd (5`ACATCGCCAATCAGCTTGG 3`), Oct4 Rev 
(5`AGAACCATACTCGAACCACATCC 3`), Klf4 Fwd 
(5`GCACACCTGCGAACTCACAC 3`), Klf4 Rev 
(5`CCGTCCCAGTCACAGTGGTAA 3`), Nanog Fwd 
(5`CCTCCAGCAGATGCAAGAACTC 3`), Nanog Rev 
(5`CTTCAACCACTGGTTTTTCTGCC 3`). GAPDH Fwd (5` 
GCACAGTCAAGGCCGAGAAT 3`), GAPDH Fwd. (5` 
GCCTTCTCCATGGTGGTGAA 3`). 
4.3 Results 
4.3.1 Oncogenic KrasG12D-mediated development of squamous 
papillomas is unaffected by loss of pRB-E2F interactions 
Maintenance of the G1 to S-phase restriction point is critical at preventing aberrant 
growth. The involvement of pRB in the G1 to S transition is well established however, as 
demonstrated by Cecchini et al., and others pRB-E2F interactions are dispensable for cell 
cycle arrest10,12,13. As derepression of E2F target genes in the Rb1G/G mice was unable to 
lead to tumorigeneses we attempted to stimulate aberrant growth signalling in vivo by 
combining the Rb1G mutation with oncogenic KrasG12D expression12,17. The KrasG12D  
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Figure 4.1: Schematic representation of Ras signaling. 
Following binding of growth stimulatory ligands receptor tyrosine kinases (RTKs). This 
signals the activation of son of sevenless (SOS) and GRB2 which activate Ras. Following 
activation, Raf is recruited to the membrane and phosphorylated by Ras. This signaling 
cascade results in the activation of MEK1/2 and ERK1/2 by phosphorylation. Erk1/2 then 
translocates to the nucleus and activates the transcription factor Myc/Max which results 
in inhibition of transcription of cell cycle repressors such as p27. Additionally, Myc/Max 
increases the expression of cell cycle promoting factors such as Cyclin D as well as E2F 
target genes.  
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mutation results in constitutive Kras signalling in the absence of normal growth 
signalling17. Signalling through Kras results in a cascade that leads to an active Myc/Max 
transcription factor which can regulate gene transcription driving the cell cycle (Figure 
4.1). In particular, a decrease in the expression of Cdkn1b (p27) as well as an increase in 
Cyclin D results in increased hyperphosphorylation of pRB and increased E2F activity3. 
Additionally, the Myc/Max transcription factor can also induce the transcription of E2F 
target genes further driving the cell into S-phase22. The inability of Rb1G to associate 
with E2F suggests that in the face of increased E2F expression, the tumor-suppressive 
ability of pRB would be compromised by this mutation. To induce expression of 
oncogenic KrasG12D in adult tissues we used a Lox-Stop-Lox system which can activate 
oncogenic KrasG12D expression following Cre recombinase activity17. This knock-in 
strain was introduced into the Rb1G/G mouse line along with a transgene encoding Cre 
recombinase fused to ERT2 hormonal response element12,17,18. 
Both control LSL-KrasG12D; Ert2-Cre+mice and experimental Rb1G/G; LSL-KrasG12D; 
Ert2-Cre+ mice were produced at normal Mendelian ratios (Table 4.1). Typically, to 
activate Ert2-Cre via tamoxifen injection, 75mg/kg is delivered intraperitoneally once per 
day for a period of 5 days. However, following this protocol both control and 
experimental mice reached endpoints within one week of the final injection without 
tumor development. To induce more sporadic activation of KrasG12D expression and 
thereby prevent the rapid decline of treated animals, we used an altered dosing regiment. 
Eight-week-old Rb1G/G; LSL-KrasG12D; Ert2-Cre+ and LSL-KrasG12D; Ert2-Cre+ control 
animals were injected with one dose of 75mg/kg tamoxifen. Tamoxifen then binds the 
ERT2 element and shuttles Cre recombinase into the nucleus, removing the stop  
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Table 4.1: Frequency of generation of Rb1G/G; KrasG12D; Ert2-Cre+ compound 
mutant mice. 
 
 
Rb1G/+; KrasG12D x 
Rb1G/+; Ert2-Cre+ 
 Observed Expected 
Rb1+/+ 12 8 
Rb1+/+; KrasG12D 7 8 
Rb1+/+; Ert2-Cre+ 9 8 
Rb1+/+; KrasG12D; Ert2-Cre+ 9 8 
Rb1G/+ 15 17 
Rb1G/+; KrasG12D 10 17 
Rb1G/+; Ert2-Cre+ 20 17 
Rb1G/+; KrasG12D Ert2-Cre+ 15 17 
Rb1G/G;  18* 8 
Rb1G/G; KrasG12D 6 8 
Rb1G/G; Ert2-Cre+ 6 8 
Rb1G/G; KrasG12D Ert2-Cre+ 8 8 
Total 135  
The indicated genotypes of mice were crossed and all resulting progeny were genotyped. 
The number of live animals obtained at two weeks of age is indicated for each genotype 
and the expected number based on Mendelian inheritance is indicated. * denotes 
significance as determined by chi-squared test. 
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cassette in front of the oncogenic KrasG12D allele allowing for expression (Figure 4.2A). 
These mice were then monitored for tumor formation. Both Rb1G/G; LSL-KrasG12D; Ert2- 
Cre and control LSL-KrasG12D; Ert2-Cre mice developed masses very early after 
tamoxifen injection with an average survival of 56.5 days and 65 days post injection 
respectively (Figure 4.2B). Necropsy also identified masses forming in the interior of the 
mouth as well as on the stomach in both genotypes (Figure 4.2C). H&E staining of  
sections of the masses removed from these animals identified them as squamous cell 
papillomas (Figure 4.2C). Further, these masses appear to arise out of esophageal tissue 
and have similar structures in both the mouth and stomach tumors (Figure 4.2C). 
Importantly, the same tumor development as well as lifespan was seen both control 
KrasG12D animals as well as experimental Rb1G/G KrasG12D cohorts (Figure 4.2BC). 
Taken together this cross demonstrates that tumor development caused by oncogenic 
KrasG12D expression is unaffected by the Rb1G mutation in the context of the squamous 
papillomas which were produced. Conclusions about the interaction between oncogenic 
Kras and the Rb1G mutations in other tumor types would require a tissue specific 
approach.  
4.3.2 Loss of E2F repression by pRB exacerbates the tumor 
phenotype of Trp53-/- animals 
In chapter 2 we have shown that the combination of Rb1G mutation and the deletion 
of p27 lead to an ineffective DNA damage response and ultimately tumor formation8. 
This ineffective response to DNA damage seen in Rb1G/G; Cdkn1b-/- cells and animals 
seems to suggest that Rb1G, which is incapable of inhibiting E2Fs, is still involved in the  
114 
 
 
 
Figure 4.2: Expression of oncogenic KrasG12D leads to rapid tumor development 
independent of E2F regulation. 
(A) Schematic representation of tamoxifen induced expression of KrasG12D. Following 
injection, tamoxifen binds to the ERT-Cre fusion protein leading to nuclear translocation. 
Cre is then able to excise the stop cassette ahead of KrasG12D resulting in expression. (B) 
Kaplan Meier analysis of tumor-free survival of indicated genotypes. Mice were 
monitored until natural endpoint, those having tumors are shown. Rb1G/G; KrasG12D (56.5 
days post injection) (n=6) and KrasG12D mice (65 days post injection) (n=4) are not 
statistically different from one another using the log rank test (p=0.475). (C) Whole 
mount and H&E analysis of squamous papillomas that develop in KrasG12D mice. 
Squamous papillomas developed out of the mouth as well as stomach of both control 
KrasG12D and Rb1G/G; KrasG12D animals. Scale bars are equal to 100µm. 
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DNA damage response8. To determine if insensitivity to DNA damage is the critical 
factor resulting in tumor development in Rb1G/G; Cdkn1b-/- animals, Rb1G/G mice were 
crossed into the Trp53-/- background which are known to have elevated levels of DNA 
damage8,20. Under normal circumstances, following DNA damage ATM phosphorylates 
and activates p5323. Active p53 then stimulates transcriptional programs leading to the 
expression of genes that result in cell cycle arrest and apoptotic signalling23. Importantly, 
p53 activation triggers the expression of Cdkn1a which encodes for p21 a CKI capable of 
inhibiting the function of Cyclin/CDK complexes24. This in turn leads to the 
hypophophorylation of pRB and subsequent cell cycle arrest (Figure 4.3).  
Once again both Trp53-/-, and Rb1G/G; Trp53-/- mice were produced at appropriate 
Mendelian frequencies (Table 4.2). The tumors inherent to the p53 knockout model 
typically present as lymphomas and occasional sarcomas beginning around 6 months of 
age for homozygous deletion (Figure 4.4B)20. The introduction of the Rb1G mutation into 
the p53 null mouse line resulted in a decrease of both overall survival as well as tumor 
free survival in the Rb1G/G; Trp53-/- animals (150 days) relative to Trp53-/- controls (194.5 
days) (Figure 4.4AB).  
Consistent with previous studies Trp53-/- animals presented with thymic lymphomas 
(77%) and sarcomas (33%) (Figure 4.4C)20. Interestingly, while most of the Rb1G/G; 
Trp53-/- animals developed thymic lymphomas (62.5%), 38.5% of animals spontaneously 
died very young (average of 125 days) with no discernible tumor phenotype (Figure 
4.4A). Whole mount and H&E stained sections of these tumors confirmed that those 
masses that did develop in Rb1G/G; Trp53-/- animals were thymic lymphomas  
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Figure 4.3: Schematic representation of p53 cell cycle arrest signaling. 
Following genetic insults in the form of DNA damage, p53 is activated though ATM-
mediated phosphorylation. Following activation p53 can induce the transcription of a 
variety of genes that are critical to the activation of apoptotic and cell cycle arrest 
mechanisms. In particular, the expression of Cdkn1a, is primarily responsible for 
initiating a p53 dependent cell cycle arrest. Following expression, p21 is then capable of 
inhibiting Cyclin/CDK complexes which results in the hypophosphorylation of pRB and 
subsequent cell cycle arrest. 
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Table 4.2 Frequency of generation of Rb1G/G; Trp53-/- compound mutant mice. 
 
 
Rb1G/+; Trp53+/- x 
Rb1G/+; Trp53+/- 
 Observed Expected 
Rb1+/+; Trp53+/+ 33* 19 
Rb1+/+; Trp53+/- 44 38 
Rb1+/+; Trp53-/- 13 19 
Rb1G/+; Trp53+/+ 45 38 
Rb1G/+; Trp53+/- 80 76 
Rb1G/+; Trp53-/- 19* 38 
Rb1G/G; Trp53+/+ 20 19 
Rb1G/G; Trp53+/- 39 38 
Rb1G/G; Trp53-/- 12 19 
Total 305  
 
The indicated genotypes of mice were crossed and all resulting progeny were genotyped. 
The number of live animals obtained at two weeks of age is indicated for each genotype 
and the expected number based on Mendelian inheritance is indicated. * denotes 
significance as determined by chi-squared test. 
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Figure 4.4:  Loss of E2F regulation by pRb exacerbates Trp53-/- tumor development. 
(A) Kaplan Meier analysis of overall survival of indicated genotypes. Mice were 
monitored until natural endpoint. Rb1G/G; Trp53-/- (140 days) (n=8), Trp53-/- (194.5 days) 
(n=12) are statically significant from one another using the log-rank test (p<0.0001). (B) 
Kaplan Meier analysis of tumor-free survival of indicated genotypes. Mice were 
monitored until natural endpoint, those having tumors are shown. Rb1G/G; Trp53-/- (150 
days) (n=5), Trp53-/- (194 days) (n=9) are statically significant from one another using 
the log-rank test (p=0.0046). (C) Whole mount and H&E analysis of thymic lymphomas 
found in both Rb1G/G; Trp53-/- and Trp53-/- mice. Scale bars are equal to 50µm. 
119 
 
 
(Figure 4.4C). Given the propensity of double mutant Rb1G/G; Trp53-/- mice to 
phenocopy Trp53-/- animals it suggests that the Rb1G mutation exacerbates the Trp53-/- 
phenotype by removing an additional cell cycle checkpoint allowing for unchecked E2F 
target gene expression.  
 The correlation between defective DNA damage signalling and tumor formation 
in Rb1G/G; Cdkn1b-/- mice suggests that loss of appropriate DNA damage signaling in 
Rb1G/G mice would result in pituitary tumor formation (Chapter 2)8. However, this was 
not the case even though Trp53-/- MEFs display the same defective DNA damage 
response found in Rb1G/G; Cdkn1b-/- MEFs25,26. One possible explanation for this finding, 
is that due to the rapid morbidity of the p53 knockout mouse strain, it is difficult to 
determine if the Rb1G mutation would lead to the development of pituitary tumors over a 
longer period of time (Figure 4.4AB). Therefore, we wanted to determine the effect of 
the Rb1G mutation in a mouse model which had the same cell cycle arrest problems in 
response to DNA damage without rapid tumor development displayed by p53 knockout 
stains. To address this question we chose to use the Cdkn1a-/- knockout model lacking 
p21, which exhibits a defective cell cycle response to DNA damage without rapid 
morbidity19.  
4.3.3 Cdkn1a (p21) deletion is incapable of inducing 
tumorigenesis in the Rb1G/G background 
Following DNA damage, p53 activates a cell cycle arrest mechanism through the 
transcriptional stimulation of Cdkn1a24. The Cdkn1a gene encodes for p21 which then 
elicits a cell cycle arrest prior to DNA repair24. p21 is member of the CIP/KIP family of  
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Cyclin dependent kinase inhibitors5. As such p21 can induce a cell cycle arrest through 
the inhibition of a broad range of Cyclin/CDKs5. Importantly, previous publications have 
shown that cells lacking p21 have a defective DNA damage response similar to that 
exhibited in Rb1G/G; Cdkn1b-/- MEFs (Figure 4.5A)8,27. This included the inability to 
arrest in response to ionizing radiation (Figure 4.5A) as well as rapid immortalization in 
3T3 assays27,28. Despite these deficiencies tumor development in Cdkn1a-/- (p21 null) 
mice is rare and inconsistent in the literature depending on strain background27,29. Given 
the rarity of cancers in Cdkn1a-/- mice and the lack of DNA damage response we chose to 
combine p21 null mice with our Rb1G/G animals. By doing so we were able to determine 
if the tumor development that we found in our Rb1G/G; Cdkn1b-/- double mutant mice was 
dependent on a lack of an effective DNA damage response8. Additionally, this cross was 
used to determine whether the tumor phenotype displayed in Rb1G/G; Cdkn1b-/- mice is 
specific to p27 loss or if loss of p21 could result in the same effect8.  
 Firstly, we confirmed the overall sensitivity of Cdkn1a-/- and Rb1G/G; Cdkn1a-/- 
MEFs to DNA damage treatment (Figure 4.5A). As predicted by previous studies, p21 
null MEFs display a defective arrest in response to ionizing radiation (IR) with or without 
the inclusion of the Rb1G mutation (Figure 4.5A). Importantly, the defective arrest in 
response to IR in p21 null and Rb1G/G; Cdkn1a-/- MEFs is similar to that of Rb1G/G; 
Cdkn1b-/- MEFs (Figure 4.5A). Therefore, if the defective DNA damage response in 
Rb1G/G; Cdkn1b-/- is responsible for tumor formation, Rb1G/G; Cdkn1a-/- would be 
predicted to develop similar malignancies. Both Cdkn1a-/- and Rb1G/G; Cdkn1a-/- mice 
were produced at appropriate Mendelian ratios (Table 4.3). 
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Figure 4.5: Combination of the Rb1G mutation and loss of p21 (Cdkn1a-/-) does not 
lead to tumor formation despite defective DNA damage response. 
(A) Cell cycle analysis of MEFs following treatment with 15Gy of ionizing radiation. S-
phase was determined by BrdU incorporation and Flow Cytometry. Average of 3 
replicates are shown, error bars indicate standard deviation. * indicates p<0.05. (B) 
Kaplan Meier analysis of overall survival of indicated genotypes. Mice were monitored 
until natural endpoint. Rb1G/G; Cdkn1a-/- (419 days) (n=25), Cdkn1a-/- (442 days) (n=24) 
are not statically significant from one another using the log-rank test (p=0.9059). (C) 
Kaplan Meier analysis of tumor-free survival of indicated genotypes. Mice were 
monitored until natural endpoint, those having tumors are shown as events. Rb1G/G; 
Cdkn1a-/- and Trp53-/- are not statically significant from one another using the log-rank 
test (p=0.7919). (D) H&E analysis of the two tumors found in Rb1G/G; Cdkn1a-/- and 
Cdkn1a-/- mice. Scale bars are equal to 50µm. (E) whole mount images of pituitaries of 
aged Cdkn1a-/- and Rb1G/G; Cdkn1a-/- animals demonstrate no hyperplasia. Pituitaries are 
denoted by black arrows. 
122 
 
 
 
 
 
 
Table 4.3: Frequency of generation of Rb1G/G; Cdkn1a-/- compound mutant mice. 
 Rb1G/+; Cdkn1a+/- x 
Rb1G/+; Cdkn1a+/- 
 Observed Expected 
Rb1+/+; Cdkn1a+/+ 17 21 
Rb1+/+; Cdkn1a+/- 64* 43 
Rb1+/+; Cdkn1a-/- 26 21 
Rb1G/+; Cdkn1a+/+ 29* 43 
Rb1G/+; Cdkn1a+/- 82 86 
Rb1G/+; Cdkn1a-/- 39 43 
Rb1G/G; Cdkn1a+/+ 19 21 
Rb1G/G; Cdkn1a+/- 37 43 
Rb1G/G; Cdkn1a-/- 29 21 
Total 342  
The indicated genotypes of mice were crossed and all resulting progeny were genotyped. 
The number of live animals obtained at two weeks of age is indicated for each genotype 
and the expected number based on Mendelian inheritance is indicated. * denotes 
significance as determined by chi-squared test. 
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 Surprisingly however, despite the homology between p21 and p27, Rb1G/G; 
Cdkn1a-/- mice showed no change in overall survival as compared to Cdkn1a-/- controls 
(Figure 4.5B). Furthermore, at endpoint the vast majority of these mice displayed no 
observable masses (Figure 4.5C). Out of the 25 Rb1G/G; Cdkn1a-/- mice 1 had a mass in 
the lower abdomen which has been identified as an angiosarcoma (Figure 4.3CD). 
Additionally, one Cdkn1a-/- mouse had an oncocytoma which arose out of the kidney 
(Figure 4.3CD). Importantly, these animals were far older, 334 and 485 days 
respectively, than Rb1G/G; Cdkn1b-/- mice succumbing to pituitary tumors, which had an 
average tumor free survival of 214 days (Chapter 2)8. Furthermore, the pituitaries of 
these mice showed no overt aberrant growth, whereas tumor formation in Rb1G/G; 
Cdkn1b-/- mice ubiquitously occurred in the intermediate lobe of the pituitary (Figure 
4.5E)8. 
Given the homology between p21 and p27 and the similar inability to respond 
properly to DNA damage, it is surprising that p21 loss does not synergize with loss of 
E2F repression as p27 does5,8. This suggests that p27 is playing a unique tumor-
suppressive role which can not be compensated for by p21 (Figure 4.3A)28. As 
mentioned in the introduction Rb1+/- animals develop normally into adulthood, however 
following loss of heterozygosity, Rb1-/- cells result in pituitary tumor formation30,31. 
Additionally Cre-mediated deletion of pRB in the pituitary of mice have resulted in the 
same malignancy32. Several studies have attempted to modulate this phenotype through 
the deletion of various genes (Table 4.4, 4.5). Co-deletion of p21, p27 or p53 in the 
Rb1+/- background lead to a decreased tumor-free survival with the loss of additional 
tumor suppressors (Table 4.4)33-35. By contrast co-deletion of Skp2 or E2f1 in the Rb1+/-  
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Table 4.4: Effect of codeletion of various genes on pituitary tumor development in 
Rb1+/- mice. 
Gene Survival of 
Rb1+/- 
Survival of 
compound 
mice 
Change Pathology Citation 
Id2-/- 276 days 334 days +58 days Pituitary tumors 36 
Skp2-/- ~380 days No 
tumorigenesis 
No 
tumors 
Pituitary tumors 37 
Cdkn1b-/- 337 days 178 days -159 days Pituitary tumors 34 
Cdkn1a-/- 340 days 261 days -79 days Pituitary tumors 33 
Trp53-/- 357 days 105 days -252 days Lymphoma 
(40%), Pituitary 
(33%), Sarcoma 
(14%), Other 
(13%) 
35 
E2f1-/- 340 days 521 days 43 Pituitary tumors 
(62%) 
38 
 
Table 4.5: Effect of codeletion of Sox2 on pituitary tumor development in 
conditional Rb1-/- mice. 
Control 
Genotype 
Experimental 
Genotype 
Survival of 
mice 
Phenotype 
of control 
Experimental 
Phenotype 
Citation 
Rb1f/f Rb1f/f; 
POMCCre 
125 days No tumors 
(14 months) 
Pituitary 
tumors 
32 
Rb1f/f; 
Rosa26CreER 
Rb1f/f; Sox2f/f; 
Rosa26CreER 
Sacrificed 
at 9 weeks 
post 
injection 
Pituitary 
tumors 
No tumors 39 
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background resulted in the rescue of pituitary tumorigeneses (Table 4.4)37,38. As both 
E2F1 and Skp2 promote cell cycle entry and are both inhibited by pRB activity, the 
deletion of these genes not surprisingly significantly reduced tumorigenesis (Table 4.4).  
 In addition to the deletion of these tumor-suppressors and oncogenes, two studies 
have shown that the pituitary tumor phenotype is also rescued by the deletion of the 
pluripotency factors Id2 and Sox2 (Table 4.4, 4.5)36,39. Sox2 is of particular interest as it 
is a marker of pluripotency in the intermediate lobe of the pituitary40. This suggests that 
the ability to maintain pluripotency is necessary to develop pituitary tumors in this 
background39. These stem-like cells could be far easier to be transformed resulting in 
tumor formation. Additionally, previous work has shown that both Rb1-/- cells and our 
Rb1G/G cells reprogram into stem cells more efficiently than wildtype controls following 
expression of reprogramming factors (Oct4, Klf4, cMyc, Sox2)39. This raises the 
possibility that E2F repression plays a role in maintaining a differentiated state.  
Interestingly, while p21 and p27 play similar roles in their ability to regulate the cell 
cycle through the inhibition of Cyclin/CDK complexes, Cdkn1b-/- cells show differential 
reprogramming efficacy when compared to Cdkn1a-/- cells5,41. When only 2 
reprogramming factors (Oct4, Klf4) were expressed in p21 and p27 null cells, p27 null 
cells reprogrammed into stem cells at 4 times the rate of p21 null cells41. Additionally, 
the expression of the pluripotency factor Sox2, which is necessary for tumor development 
in Rb1-/- pituitaries, is regulated by p2741. Chromatin immunoprecipitation has shown that 
both pRB and p27 are capable of binding to the upstream enhancer SRR2 influencing 
Sox2 expression39,41.  
126 
 
 
To determine if there is an increased level of pluripotency factors inherent to the 
Rb1G/G; Cdkn1b-/- MEFs we isolated RNA and performed qRT-PCR expression analysis 
of 4 keys stem cell factors (Sox2, Oct4, Klf4, and Nanog). Overall, we found no 
significant difference between the various genotypes tested, likely due to the huge 
amount of variability present across samples (Figure 4.6). However, as stem cell factors 
are expressed at very low levels in non-stem cells it is not surprising from one population 
to the next the expression of these factors may vary wildly. In summary, the lack of a 
tumor phenotype in Rb1G/G; Cdkn1a-/- animals lacking 21 as compared to the pituitary 
tumors formed in Rb1G/G; Cdkn1b-/- mice missing p27, suggests that p27 is playing a 
unique tumor suppressive role in addition to cell cycle arrest mechanisms following DNA 
damage in the context of the Rb1G mutation (Figure 4.5BC)8. This role may include 
prevention of stem cell like reprogramming, however more studies are required to fully 
address these questions. 
4.4 Discussion 
In this chapter, we aimed to investigate the tumor-suppressive abilities of pRB 
independent of E2F transcription factor repression. We show that, while the Rb1G 
mutation does exacerbate the tumor development of Trp53-/- mice, there is no effect on 
tumor-free survival in the presence of oncogenic KrasG12D expression, nor following loss 
of p21 (Cdkn1a-/-). In conjugation with the results presented in chapter 2 demonstrating 
that Rb1G/G; Cdkn1b-/- animals, lacking p27, form pituitary tumors, these genetic crosses 
provide an interesting picture of how pRB-E2F interactions influence tumor-suppression 
in the face of various cancer causing mutations8.  
 
127 
 
 
 
 
Figure 4.6: Expression of pluripotency factors Sox2, Klf4, Oct4, and Nanog, in 
Rb1G/G; Cdkn1b-/- MEFs. 
Expression of genes was determined by qRT-PCR, normalized to GAPDH. Average of 3 
replicates is shown, error bars indicate standard error. No statistically significant 
differences were found among any genotypes as determined by one-way ANOVA and 
Tukey’s test (p>0.05). 
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The expression of the Rb1G mutation in the presence of oncogenic KrasG12D had no 
effect on tumor free survival (Figure 4.2B). One compelling explanation for this finding 
is uncovered through analysis of the method by which oncogenic Kras leads to tumor 
formation. Overall, oncogenic KrasG12D causes a signalling cascade which results in both 
the expression of E2Fs, an increase in Cyclin/CDK complexes and the suppression of p27 
activity14,15. Importantly, although KrasG12D activation results in increased activity of 
E2Fs, which can not be sequestered by pRBG, the increased Cyclin/CDK activity results 
in the hyperphosphorylation of pRB3. This in turn leads to the compaction of the pRB 
protein and the complete disruption of both the pRB pocket domain and the LxCxE 
binding cleft which eliminates the E2F regulatory and p27 stabilization functions of pRB-
mediated cell cycle control respectively4. As such, the expression of oncogenic KrasG12D 
results in the hyperphophorylation of pRB and any effect that pRBG could have been 
masked by the complete disruption of pRB-mediated cell cycle control. Alternatively, the 
extremely fast rate at which expression of KrasG12D induces tumor development it is 
possible that the Rb1G mutation could not cooperate to achieve any change in tumor 
latency. Potentially future studies using tissue specific Cre driver lines may cause slower 
growing tumors and the Rb1G mutation may alter the kinetics. 
Our findings in chapter 2 demonstrated that the combined loss of pRB-E2F repression 
and p27 results in a defective DNA damage response and eventual pituitary tumor 
formation (Chapter 2)8. Furthermore, this defective arrest was also seen in embryonic 
pituitaries of combined mutant mice (Rb1G/G; Cdkn1b-/-)8.  As these findings suggest a 
defective DNA damage response is involved in the tumorigenesis observed, we aimed to 
better understand the involvement of pRB-E2F interaction in this paradigm. By 
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introducing our Rb1G mutation into the Trp53-/- background we determined the tumor-
suppressive capabilities of Rb1G in the presence of elevated DNA damage inherent to 
Trp53-/- mice20. The fact that Rb1G/G; Trp53-/- mice develop similar tumors with faster 
kinetics to that of Trp53-/- controls indicates that pRB-E2F interactions are important for 
regulating cellular responses to DNA damage, but not the tumor tropism (Figure 
4.4AB)20.  
Interestingly, this function must lie outside of canonical understanding of pRB 
activation following DNA damage. Under wild-type conditions, DNA damage would be 
identified and ATM/ATR kinases would stabilize and activate p53 through 
phosphorylation15. This in turn would upregulate a number of genes, one of which is p21 
encoded by the CDKN1A gene15. Once expressed, p21 is then able to bind to and inhibit 
the activity of Cyclin/CDK complexes maintaining pRB in a hypophosphorylated state4,5. 
The fact that Rb1G/G; Trp53-/- show decreased tumor-free survival as compared to 
controls suggests that pRB is still playing a role in tumor-suppression in the presence of 
DNA damage despite the inability of signaling to propagate via p53 and p21 to pRB24. 
One possible explanation for this is that, Rb1G/G; Trp53-/- mice have reduced survival 
simply due to cells harboring an additional mutation in a critical binding pocket of an 
important tumor suppressor, the general E2F interacting site. This line of thinking would 
indicate that the pRB and p53 pathways in this context are functioning independently and 
the loss of p53 as well as E2F transcriptional repression simply makes a cell more 
amenable to tumorigenesis. 
Lastly, to test the effect of the Rb1G mutation in a mouse model harboring a defective 
DNA damage response, we combined our Rb1G/G mutant mouse with the Cdkn1a-/- 
130 
 
 
background which have a deletion of p21. Given the high degree of homology between 
p21 and p27 it is surprising that Rb1G/G; Cdkn1a-/- mice do not show any tumor incidence 
in contrast to Rb1G/G; Cdkn1b-/- animals, which ubiquitously develop pituitary tumors 
(Figure 4.5BC)8. p21 and p27 are both members of the CIP/KIP family of CKIs which 
influence cell cycle control through the inhibition of Cyclin/CDK activity5. When 
combined with the Rb1G mutation, p27 deletion prevents cells from responding 
appropriately to DNA damage, potentially leading to the development of the pituitary 
tumors observed8. Importantly, the defective cell cycle arrest in response to DNA damage 
exhibited in the Rb1G/G; Cdkn1b-/- cells is also present in cells null for p21 (Figure 
4.5A)27,28. Together this indicates that p27 must be playing a specific role in preventing 
tumor formation when pRB-E2F interactions are disrupted that can’t be compensated for 
by p21, and is therefore is beyond influencing DNA damage induced cellular arrest.  
One role of p27 that is unique among CIP/KIP family members is the ability to 
regulate the expression of the Sox2 gene through the regulation of the SRR2 enhancer41. 
Sox2 is a pluripotency factor that is critical to the development of the pituitary40. 
Additionally, Sox2 is required to allow for tumor formation in Rb1-/- pituitaries39. This 
expression of a pluripotency factor could lead to a more stem-like phenotype in Rb1G/G; 
Cdkn1b-/- pituitaries resulting in transformation and subsequent tumor formation. 
However, when analyzed by qRT-PCR we found no differences in the overall level of 
these factors in any of the genotype tested (Figure 4.6). Importantly, in this experiment 
we found a huge degree of variability in the expression of these genes likely due to their 
overall low abundance in non-stem cells. Additionally, stem-cell reprogramming occurs 
at a cell to cell basis. Even when cells are reprogrammed through the expression of the 
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canonical reprogramming factors (Oct4, Klf4, cMyc and Sox2) this is a rare event39. 
Therefore, the lack of any meaningful change in the expression of the stem cell markers 
(Sox2, Klf4, Oct4 and Nanog) in MEF population is perhaps unsurprising as any 
alteration can be drowned out by population effects (Figure 4.6). While we have not 
discerned a direct link between our Rb1G/G; Cdkn1b-/- MEFs and increased amenability to 
stem cell reprogramming this remains a formal possibility which requires further 
investigation. 
Overall, we show that our Rb1G mutation can enhance the ability of cells to form 
tumors in Trp53-/- mice (Figure 4.4B). However, in the presence of the oncogenic driver 
mutation KrasG12D, the inability of pRB to regulate E2F target transcription did not affect 
tumor-free survival (Figure 4.2B). Finally, the surprising finding that p21 and p27 
deletion have very different phenotypic effects in our Rb1G/G mutant animals indicates 
that p27 has a unique tumor-suppressive role in the absence of pRB-E2F interactions 
(Figure 4.5C)8.  
The findings of these genetic crosses may have important implications in the practical 
use of a novel family of cancer therapeutics, CDK4/6 inhibitors by providing diagnostic 
markers for effective treatment administration. Specifically, re-activation of pRB-
mediated cell cycle control would be most effective in tumors which retain p53 activity 
and would likely not be effected p21 deletion. Finally, as oncogenic KrasG12D typically 
influences tumorigenesis through the hyperphosphorylation of pRB, use of CDK4/6 
inhibitors in these tumors would likely be an effective strategy to combat tumor growth. 
Provided, of course, that adequate inhibition of CDK4/6 can be achieved in the presence 
of oncogenic Kras. Further studies analyzing CDK4/6 inhibitors in cells harboring these 
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mutations will provide additional information towards more effective administration of 
these novel compounds. 
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Chapter 5  
5 Discussion 
5.1 Summary of findings 
The retinoblastoma tumor-suppressor protein (pRB) has been the subject of a 
significant volume of research that aims to understand the mechanism through which 
pRB can prevent tumorigenesis. Originally predicted through the genetic analysis of 
children developing retinoblastoma, pRB is now often described as the main gate-keeper 
of the G1 to S-phase transition of the cell cycle and whose activity is perturbed in a 
majority of human tumors1-3. pRB-mediated cell cycle control is maintained through the 
repression of the E2F family of transcription factors which influence the transcription of 
genes required for S-phase entry4,5. However, the function of pRB resists simplicity as a 
growing body of literature has been suggesting new roles in cell cycle control and tumor 
suppression independent of E2F transcriptional repression6-10. Building on this, Cecchini 
et al., through the development of the Rb1G/G mouse model, demonstrated that the loss of 
pRB-E2F interactions is largely dispensable for cell cycle control and tumor-
suppression11. In this thesis, by exploiting the Rb1G/G mouse model, I continued to 
explore the tumor-suppressive ability of pRB outside of pRB-E2F interactions, using a 
variety of in vitro and in vivo approaches to further characterize these interactions. 
My findings in this thesis demonstrate that cell cycle control and tumor-
suppression by pRB is multifaceted and extends beyond simple repression of E2F 
transcription factors. In chapter 2, through analysis of the Rb1G/G mouse model in 
combination with loss of p27 we present in vivo evidence of an E2F independent 
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mechanism of pRB-mediated cell cycle control through the stabilization of p27 in 
response to DNA damage12. As pRB-E2F interactions are dispensable for this function, in 
chapter 3, we next explored the various contributions to cell cycle control of 3 specific 
binding surfaces in the pRB large pocket. These experiments confirmed that the RB 
pocket domain, LxCxE binding cleft, and the E2F1 specific site all contribute to cell 
cycle control as determined by Saos-2 cell cycle arrest assays as well as in vivo analysis 
of murine livers. Finally, through a series of genetic experiments we were able garner 
further information about pRB-mediated tumor-suppression outside of E2F target gene 
repression (Chapter 4). Together the experiments presented in this thesis outline the 
importance of the entire pRB large pocket, the regulation of cell cycle, and tumor 
suppression. These findings are consistent with the prevalence of  cancer derived 
mutations that result in the complete inactivation of pRB typically through 
hyperphosphorylation3. 
5.2 Evidence for pRB as a multifaceted regulator of 
cell cycle control 
The work presented in this thesis highlights and addresses the disparity between the 
linear model of pRB-mediated tumor suppression (Figure 5.1A) and a growing body of 
literature which points towards pRB-mediated tumor suppression as a function of the 
regulation of multiple pathways controlled through the various pRB interacting domains, 
the network model (Figure 5.1B). This idea that pRB-mediated tumor-suppression is 
dependent on several interactors, provides compelling explanations for several unusual 
findings which would be odd in the context of the linear model of cell cycle control by 
pRB through E2F repression. Firstly, even though the pRB large pocket  
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Figure 5.1: pRB utilizes multiple mechanisms to ensure cell cycle control and 
tumor-suppression. 
Human tumors often contain deletion mutants of p16 or amplifications of Cyclin D 
resulting in the hyperphosphorylation of pRB. (A) Linear model of pRB-mediated tumor 
suppression. Following inactivation of pRB by phosphorylation, E2F is released and is 
responsible for driving cell entry leading to tumorigenesis. (B) Network model of pRB-
mediated tumor suppression. pRB sits at the center of a network controlling at least three 
methods of cell cycle control and tumor suppression: E2F repression, p27 stabilization 
and regulation of E2F1 via the pRB-E2F1 specific interaction. 
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is the minimal domain necessary both for E2F interactions and to initiate a cell cycle 
arrest in Soas-2 cells, this region also contains the LxCxE and specific site binding 
surfaces (Figure 1.2B)13,14. Importantly however, later studies exploiting pRB variants 
which specifically disrupt pRB-E2F interactions demonstrated that pRB could still retain 
some level of cell cycle control despite the inability of pRB to regulate E2F target gene 
expression10,15. Additionally, investigation of viral oncoproteins capable of inactivation 
of pRB, in particular E1A, required the elimination of both pRB-E2F interactions as well 
as LxCxE interactors through the stable binding of E1A’s CR1 and CR2 domains to 
pRB16. This notion that the ability of pRB to regulate the cell cycle is mediated both by 
the pocket domain and the LxCxE binding cleft is further evidenced by the 
conformational changes that occur to pRB following hyperphosphorylation6. 
Hyperphosphorylation results in the compaction of the pRB protein and the blocking of 
both the pRB pocket domain as well as the LxCxE binding cleft6. Taken together these 
findings provide a solid foundation which suggests that the role of pRB in regulating the 
cell cycle extends well beyond the repression of E2F transcription factors. Finally, our 
lab has produced three strains of mice which target the three binding surfaces discussed 
in this thesis: the pocket domain (Rb1G/G), the LxCxE binding cleft (Rb1L/L) and the pRB-
E2F1 specific interaction (Rb1S/S)8,11,17. These animals are viable and develop normally, 
which is in direct contrast to Rb1-/- mice which are embryonic lethal further supporting 
the notion that pRB regulates cell cycle control and tumor suppression through a 
multifaceted approach11,18.   
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5.3 Prevalence of perturbations to pRB function in 
cancer 
Given that pRB acts as a critical gate-keeper to cellular division it is perhaps 
unsurprising that the pRB pathway is perturbed in a large majority of human cancers3. 
Interestingly however, mutations in pRB itself is relatively rare outside of small cell lung 
cancer, retinoblastoma and osteosarcoma (Figure 5.2A)3. Typically, mutations in the 
pRB pathway occur upstream of pRB (Figure 5.2B)3. These mutations typically include 
amplifications of Cyclins, or their catalytic partner CDK, as well as deletions of Cyclin 
dependent kinase inhibitors (CKIs) (Figure 5.2B). The functional consequence of these 
alterations would be the hyperphosphorylation of pRB and subsequent loss of binding to 
both the pRB pocket domain and the LxCxE binding cleft3,6. Furthermore, the majority of 
those mutations that do occur within the coding sequence of pRB typically result in the 
formation of novel stop codons (Figure 5.2C). This in turn creates a non-functional 
truncated protein. Finally, the small subset of mutations in the pRB coding sequence that 
do result in missense changes are equally spread across the coding region (Figure 5.2D). 
Using a binomial distribution test with a Bonferroni correction we determined if any of 
the missense changes occurred at a frequency higher than expected (Figure 5.2D). While 
some amino acid changes did appear more often than expected, all of them are buried in 
the interior of the pocket domain of pRB based on previous analysis and are not likely to 
influence interactions19. However, these changes substitute small amino acids for large 
ones, which could significantly disrupt the overall structure of pRB leading to a 
dysfunctional protein.  
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Figure 5.2: Direct pRB mutation is relatively rare in human cancers and mutations 
that do exist result in null alleles. 
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Figure 5.2: Direct pRB mutation is relatively rare in human cancers and mutations 
that do exist result in null alleles. 
(A) Incidence of RB1mutation, deletion or amplification in the ten most common human 
malignancies. Data obtained from C-bio portal (2017). (B) Incidence of p14, p15, p16, 
p18, p21, p27, CyclinA1-2, B, D1-3, E1-2, CDK1/2/4/6 mutation, deletion or 
amplification in the ten most common human malignancies. Data obtained from C-bio 
portal (2017). (C) Breakdown of coding sequence mutations in RB1 and TP53 Data 
obtained from C-bio portal (2017). (D) Alignment of cancer derived mutations occurring 
in the RB1 coding region, as curated by C-bio portal (2017). (E) Alignment of cancer 
derived mutation occurring in the TP53 coding region, as curated by C-bio portal (2017). 
Dashed lines indicate threshold for significance of p<0.001 of mutational frequency 
(RB1=4 and TP53=27) as determined by binomial distribution with a Bonferroni 
correction. 
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The lack of hotspot mutations in critical interaction domains of RB1 is peculiar given 
the importance prescribed to pRB-E2F interactions in pRB-mediated tumor suppression. 
By comparison, other tumor suppressors such as TP53 and PTEN are dominated by 
missense mutations that disrupt well defined hotspots which occur within critical 
structures of the protein such as the DNA binding domain of p53 and the phosphatase 
domain of PTEN (Figure 5.2E)20,21. The fact that pRB is inactivated in the majority of 
human cancers through hyperphosphorylation or nonsense substitutions suggests that 
pRB is a crucial tumor-suppressor that must be overcome to allow for cancer 
development and progression3. Secondly, the lack of missense mutations in the RB1 gene 
demonstrates that the tumor suppressive function of pRB is likely not limited to a single 
interaction as is the case for p53 through its DNA binding domain (Figure 5.2C-E)21. 
Instead these findings imply that multiple functions of pRB contribute to its tumor-
suppressive functions and as such, disruption of the whole protein through deletion, 
truncation, or hyperphosphorylation is more prevalent in human tumors (Figure 5.2B-
D)3. Moreover, this hypothesis is supported by our data which suggested that at least 3 
different binding surfaces contribute to the cell cycle control as mediated by pRB 
(Chapter 3). Finally, the requirement for additional tumor-suppressive pathway 
disruptions in the Rb1G/G background is consistent with the complete disruption of pRB 
function through hyperphosphorylation or truncation seen in human tumors. (Figure 
5.2B-D) (Chapter 2, 4)11,12. 
5.4 Non-canonical functions of p27 
One of the most striking findings presented in this thesis is the stark phenotypic 
difference between Rb1G/G; Cdkn1a-/- mice, lacking p21 and Rb1G/G; Cdkn1b-/- mice 
144 
 
 
which have a deletion of p27. As discussed in the results chapters, Rb1G/G; Cdkn1a-/- 
mice, deficient for p21, showed relatively limited overt phenotypes, with the 
development of only 1 malignancy out of 25 animals (Figure 4.5C). Importantly there 
was no difference in terms of overall or tumor free survival when compared to Cdkn1a-/- 
controls (Chapter 4). By comparison, Rb1G/G; Cdkn1b-/- mice, lacking p27, ubiquitously 
developed pituitary tumors with a tumor free survival of 214 days, while control Rb1G/G 
and Cdkn1b-/- animals showed no tumor development (Chapter 2)12. Taken together, 
these results indicate that p27 is playing a unique role in regulating pRB-mediated tumor 
suppression. This is surprising considering there is a high degree of homology between 
p21 and p27 and the fact that both contribute to the regulation of the cell cycle through 
the inhibition of a broad range of CDKs22. As deletion of p21 in the Rb1G/G background 
did not result in tumor formation we can conclude that p27 is influencing pRB in a 
manner that is independent of cell cycle control in the presence of DNA damage as this is 
also defective in Cdkn1a-/- and Rb1G/G; Cdkn1a-/- MEFs lacking p21. 
In addition to the ability of p27 to influence the cell cycle, through the inhibition of 
CDKs, non-canonical roles in tumor suppression for p27 have been described23. 
Interestingly, some of these alternative functions of p27 are tumor-suppressive whereas 
others are oncogenic23. As discussed in chapter 4, p27 has been implicated in the 
maintenance of stemness of cells, a characteristic of tumor cells, and in particular cancer 
stem cells (CSCs) which can give rise to metastasis23,24. Overall p27 levels are relatively 
low in undifferentiated cells and differentiation coincides with an increase in p2725,26. 
Moreover, p27 has been shown to be a transcriptional repressor of SOX2 in different cell 
lines27. Furthermore, Cdkn1b-/- animals lacking p27, display increased expression of Sox2 
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in a variety of tissues27. Finally, Li et al. also demonstrated that the gigantism phenotype 
displayed in some strains of Cdkn1b-/- animals can be rescued with the co-deletion of 
Sox2, implying that Sox2 overexpression in the absence of p27 can result in aberrant 
growth27. This result together with the finding that both Rb1G/G and Cdkn1b-/- MEFs 
reprogram more efficiently than wildtype controls, suggests a potential mechanism of 
tumorigenesis in Rb1G/G; Cdkn1b-/- animals27,28. The role for p27 in transcriptional 
repression also extends beyond the regulation of Sox2, through the formation of 
transcriptional repressor complexes with p130 and E2F429. This complex is then capable 
of recruiting co-repressors such as HDACs which can compact the DNA around various 
target genes including those involved in RNA processing and the cell cycle29. Importantly 
while this repression is lost following p27 deletion, a mutant version of p27, which is 
incapable of inhibiting CDKs (p27CK) is as efficient as wildtype in repressing 
transcription29.  
Critical to the function of p27 is its subcellular localization, cytoplasmic or nuclear. 
While the ability of p27 to inhibit Cyclin/CDKs and transcriptionally repress genes 
involved in cell cycle, RNA processing and pluripotency occurs in the nucleus, additional 
roles for p27 in the cytoplasm have also been described30,31. Following phosphorylation 
of p27 on S10, p27 is exported from the nucleus32. However, the ramifications of 
cytoplasmic p27 are unclear as p27 appears to have both tumor-suppressive and 
oncogenic functions23,30,32,33. Cytoplasmic p27 can inhibit cell cycle progression through 
the disruption of the Ras signalling cascade30. Through interaction with GRB2, p27 can 
attenuate Ras signalling by disrupting GRB2-SOS interactions30. This in turn prevents the 
activation of the Ras signalling cascade30. Consistent with this finding, in the absence of 
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p27, Ras signalling remains activated at a higher level than controls resulting in Erk1/2 
phosphorylation, MAPK target gene expression, and faster cell cycle entry33.  
5.5 Cytoplasmic p27 regulates cellular migration and 
invasion 
In opposition to the tumor suppressive functions described above, cytoplasmic p27 
has also been shown to be tumorigenic through the regulation of actomyosin31. Indeed, 
cytoplasmic p27 is a marker of poor prognosis in melanoma34. Additionally, mouse 
models harboring a mutation disrupting the S10 site required for cytoplasmic localization 
of p27 (p27S10A), are resistant to tumor development in response to urethane treatment32. 
Following cytoplasmic localization, p27 associates with RhoA, inhibiting RhoA from 
becoming activated by GTP31. This inhibition of the RhoA-ROCK pathway results in the 
loss of actomyosin stability and leads to increased migration and invasion31. However, 
this promotion of migration by p27 is not universal and in several cell types p27 has been 
shown to inhibit migration35-38. 
Overall, several non-canonical functions of p27 have been described, which may help 
to understand why Rb1G/G; Cdkn1b-/- animals developed pituitary tumors where as 
Rb1G/G; Cdkn1a-/- animals, deficient for p21, generally showed no tumor phenotype 
(Chapter 2,4)12. It is possible that the loss of p27 results in a combination of factors 
which maintain a stem cell like state and promote proliferation through the upregulation 
of cell cycle target genes and increased Ras signalling, however further studies are 
necessary to fully elucidate this mechanism27,29,30.  
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5.6 Perspectives and therapeutic implications 
The work presented in the thesis has enhanced our understanding of pRB-mediated 
cell cycle control and tumor-suppression. Using a variety of techniques, we have shown 
that the linear model of pRB repression of E2F target genes is incomplete (Figure 5.1A). 
Instead, pRB sits in the center of a network of regulation activating multiple downstream 
pathways which together maintain cell cycle control and prevent tumorigenesis (Figure 
5.1B). This multifaceted approach to cell cycle regulation by pRB provides a number of 
redundant mechanisms, through which the cell can prevent tumorigenesis. This finding is 
also supported by the relative rarity of missense mutation in the Rb1 coding sequence 
(Figure 5.2D). Instead, cancers typically harbor mutations in upstream pathway 
members, which result in the hyperphosphorylation of pRB and subsequent functional 
inactivation (Figure 5.2AB). This method of pRB inactivation through phosphorylation 
allows the possibility of therapeutic intervention through the inhibition of the upstream 
kinases responsible for pRB phosphorylation. 
Currently there are three drugs which aim to restore pRB activity through the 
inhibition of pRB phosphorylation in cancer cells: Palbociclib (Pfizer), Ribociclib 
(Novartis) and Abemaciclib (Eli Lilly). These compounds work by inhibiting upstream 
kinases of pRB, CDK4 and CDK6. Following inhibition of CDK4/6, pRB becomes 
hypophosphorylated and can re-activate its various cell cycle functions including those 
highlighted in this thesis. Currently, Palbociclib is approved for use in ER+ breast 
cancers in combination with letrozole. In addition, Ribociclib and Abemaciclib are in 
phase three clinical trials. To insure effectiveness of treatment by these drugs, only 
patients with wildtype pRB are given these inhibitors. However, pRB-mediated cell cycle 
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control and tumor-suppression is a product of a network of pathways which may 
influence the effectiveness of these inhibitors. Through our various genetic crosses in the 
absence of pRB-E2F interactions we have shown that loss of p27 or p53 result in 
enhanced tumorigenesis. Therefore, we would predict that the presence of both wildtype 
p27 and p53 would likely enhance the effectiveness of these CDK4/6 inhibitors in 
patients. Importantly, in addition to disrupting DNA damage response signalling, p27 
appears to play a unique, non-CKI role in regulating tumor-suppression in the absence of 
pRB-E2F interactions12. While this function is currently unknown, several non-canonical 
functions of p27 have been previously identified and largely depend on the subcellular 
localization of p2723. Therefore, in addition to the expression level and mutational profile 
of p27, subcellular localization may be a critical determinant for the effectiveness of this 
new class of CDK4/6 inhibitors.  
In the several years following the discovery of pRB, the field has been dominated by 
the linear model through which pRB is tumor-suppressive by way of regulating E2F 
transcription factors (Figure 5.1A). However, in recent years, several non-canonical 
functions of pRB have been described. Through the development and use of the Rb1G/G 
mouse model we had the unique opportunity to look at these pRB-mediated, non-E2F 
methods of cell cycle control in vivo11. Moreover, as the Rb1G/G animals avoid the 
embryonic lethality of Rb1-/- mice, using this model we can specifically study pRB 
functions in tumorigenesis as opposed to development. The fact that pRB-E2F 
interactions are dispensable for cell cycle control and tumorigenesis, indicates that other 
pathways must play significant roles in regulating cell cycle control and tumor-
suppression11. Through a variety of in vitro, cell culture and in vivo approaches we have 
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identified at least three interacting domains in the large pocket of pRB which play a role 
in modulating cell cycle control (Chapter 3). Furthermore, the loss of pRB-E2F 
regulation interacted synergistically with Cdkn1b deletion resulting in an ineffective 
DNA damage response and eventual tumor formation (Chapter 2)12. Finally, the Rb1G 
mutation dramatically shortened the lifespan of p53 null animals while not effecting the 
outcome of mice expressing oncogenic KrasG12D nor those lacking p21 (Chapter 4). 
Critically, the lack of phenotype of Rb1G/G; Cdkn1a-/- mice lacking p21 as compared to 
Rb1G/G; Cdkn1b-/- lacking p27, suggests that p27, is playing a unique role in modulating 
the tumor-suppressive function of pRB. However, the inhibition of CDKs in response to 
DNA damage cannot be ruled out as a contributing factor to the tumor development in 
Rb1G/G; Cdkn1b-/- animals. To definitively determine if the tumorigenesis observed in 
Rb1G/G lacking p27 is dependent on the ability of p27 to inhibit CDKs, Rb1G/G mice 
would have to be combined with the p27CK mutation. Overall this thesis presents several 
lines of evidence which suggest that pRB is a hub protein at the center of a network of 
functions which together result in cell cycle control and tumor-suppression.  
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Appendix A: A retinoblastoma allele that is mutated at its 
common E2F interaction site inhibits cell proliferation in 
gene-targeted mice 
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Appendix B: List of plasmids 
Name 
Genes 
Encoded Mutations 
Obtained/ 
Constructed Resistance 
Stock 
Number 
pScodon-
GST-RBLP 
GST, 
RBLP N/A F. Dick AMP 0519 
pMJC15 
GST, 
RBLP Y756W M. Cecchini AMP 0661 
pMJC02 
GST, 
RBLP R467E, K548E M. Cecchini AMP 0561 
pscodon-
GST-RB delta 
L 
GST, 
RBLP 
I753A, N757A, 
M761A S. Talluri AMP 0668 
pscodon1-
GST-RBdS 
GST, 
RBLP M851A, V852A O. Palander AMP 0528 
pMJC17 
GST, 
RBLP 
R467E, K548E, 
Y756W M. Cecchini AMP 0613 
pMJC09 
GST, 
RBLP 
R467E, K548E, 
M851A, V852A M. Cecchini AMP 0568 
pMJC22 
GST, 
RBLP 
R467E, K548E, 
Y756W, M851A, 
V852A M. Cecchini AMP 0618 
pScodon-
GST-
RBLPGSL 
GST, 
RBLP 
R467E, K548E, 
I753A, N757A, 
M761A, M851A, 
V852A M. Thwaites AMP 0735 
pCMV-β-Gal β-Gal N/A S. Salama AMP 0042 
pCMV-HA-
DP1 DP1 N/A M. Classon AMP 0094 
CMV-HA-
E2F1 E2F1 N/A F. Dick AMP 0399 
pCMV-HA-
E2F2 E2F2 N/A J. Lees AMP 0319 
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pCMV-HA-
E2F3 E2F3 N/A J. Lees AMP 0320 
CMV-myc-
Cdh1 Cdh1 N/A N. Dyson AMP 0520 
pFAD102 RB N/A F. Dick AMP 0039 
pFAD200 RB Y756W M. Cecchini AMP 0196 
pMJC03 RB R467E, K548E M. Cecchini AMP 0562 
pFAD139 RB 
I753A, N757A, 
M761A F. Dick AMP 0059 
pFAD292 RB M851A, V852A F. Dick AMP 0412 
pMJC20 RB 
R467E, K548E, 
Y756W M. Cecchini AMP 0616 
pMJC21 RB 
R467E, K548E, 
M851A, V852A M. Cecchini AMP 0617 
pMJC22 RB 
R467E, K548E, 
Y756W, M851A, 
V852A M. Cecchini AMP 0618 
CMV-RBGSL RB 
R467E, K548E, 
I753A, N757A, 
M761A, M851A, 
V852A M. Thwaites AMP 0736 
Efla 4F puro 
cMyc, 
Sox2, 
Oct4, 
KLF4 N/A J. Sage AMP 0737 
Tet O 4F 
cMyc, 
Sox2, 
Oct4, 
KLF4 N/A J. Sage AMP 0738 
Tet O Sox2 Sox2 N/A J. Sage AMP 0739 
Tet O Oct4 Oct4 N/A J. Sage AMP 0740 
Tet O cMyc cMyc N/A J. Sage AMP 0741 
172 
 
 
Tet O KLF4 KLF4 N/A J. Sage AMP 0742 
Gag/pol Gag/pol N/A J. Sage AMP 0743 
Tat Tat N/A J. Sage AMP 0744 
Rev Rev N/A J. Sage AMP 0745 
VSVG VSVG N/A J. Sage AMP 0746 
CMV p107 6x p107 
T480R, V490K, 
N556E, E560H, 
G786T, H797R S. Rubin AMP 0747 
CMV HA-
Skp2 Skp2 N/A S. Meloche AMP 0748 
CMV HA-
Skp2 S64A Skp2 S64A S. Meloche AMP 0749 
CMV HA-
Skp2 AA Skp2 S64A, S72A S. Meloche AMP 0750 
CMV HA-
Skp2 DD Skp2 S64D, S72D S. Meloche AMP 0751 
CMV RBGL 
RB Large 
Pocket 
R467E, K548E, 
I753A, N757A, 
M761A M. Thwaites AMP 0752 
CMV RBLS 
RB Large 
Pocket 
I753A, N757A, 
M761A, M851A, 
V852A M. Thwaites AMP 0753 
pScodon 
GST-RBC 
RB Large 
Pocket Y756W M. Thwaites AMP 0754 
pScodon 
GST-RBGSC 
RB Large 
Pocket 
R467E, K548E, 
M851A, V852A, 
Y756W M. Thwaites AMP 0755 
pScodon 
GST-p107 6x p107 
T480R, V490K, 
N556E, E560H, 
G786T, H797R S. Rubin AMP 0756 
pScodon 
GST-RBC 
RB C-
terminus N/A M. Thwaites AMP 0757 
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mouse 
pet30a His-
RBC 
RB C-
terminus 
mouse N/A M. Thwaites KAN 0758 
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Appendix C: List of antibodies 
Antibody 
Protein 
recognized Species Supplier CAT. # Application 
p27 (C-19) p27 Rabbit 
Santa Cruz 
Biotechnology SC-528 WB (1:500) 
Histone H3 Histone H3 Rabbit abcam ab70550 WB (1:1000) 
E2F-3 
(PG37) E2F-3 Mouse 
Santa Cruz 
Biotechnology SC-69684 WB (1:500) 
β-Actin 
(AC-74) Actin Mouse Sigma A2228 WB (1:1000) 
BrdU (B44) BrdU Mouse 
BD 
biosciences 347580 
FC (1:200), 
IF (1:50) 
CDK2 CDK2 Rabbit Millipore 07-631 IP (4µg) 
HA (3F10) HA-Tag Rat Sigma 12158167001 WB (1:1000) 
cMyc 9E11 Myc -Tag Mouse abcam ab56 WB (1:10) 
pRB G3-
245 pRB Mouse 
BD 
biosciences 554136 WB (1:1000) 
CD-20 CD-20 Mouse 
BD 
biosciences 347673 FC (1:200) 
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Appendix D: PCR conditions 
PCR Conditions Rb1 
 
Master Mix per reaction 
- 1.25 L MgCl2 (50mM)  
- 2 L dNTPs (2mM) 
- 2 L 10X PCR Buffer (200mM Tris 
pH8, 500mM KCl) 
- 1L 20M P1-F 
- 1L 20M P2-R 
- 1L 20M P3 
- 9 L Water 
- 0.75L Taq (5units/µL) 
Total   18L 
 + 2L DNA sample 
 
Reaction Conditions 
Program - RB1 370bp ST 
1. 94C 3:00 
2. 94C 0:30 
3. 60C 1:00 
4. 72C 1:00 
5. Go  to Step #2, 34 times 
6. 72C 7:00 
7. 12C hold 
 
 
Expected Results:  
 
Mutant (Null) = ~470 bp 
Heterozygote = 410 bp and ~470 bp 
Wild type = 410 bp 
 
Primers 
P1: AAT TGC GGC CGC ATC TGC 
ATC TTT ATC GC  
P2: CCC ATG TTC GGT CCC TAG 
P3: GAA GAA CGA CAT CAG CAG 
 
 
 
 
 
 
 
PCR Conditions Cdkn1b (p27) 
 
Master Mix per reaction 
- 0.5 L MgCl2 (50mM) 
- 2 L dNTPs (2mM) 
- 2 L 10X PCR Buffer (200mM Tris 
pH8, 500mM KCl) 
- 1L 20M N1 
- 1L 20M K3 
- 1L 20M K5 
- 10 L Water 
- 0.5L Taq (5units/µL) 
Total   18L 
 + 2L DNA sample 
 
Reaction Conditions 
Program - P27LCM 
1. 94C 2:00 
2. 94C 0:45 
3. 57C 0:45 
4. 72C 0:45 
5. Go  to Step #2, 34 times 
6. 72C 7:00 
7. 12C hold 
 
 
Expected Results:  
 
Mutant (Null) = 129 bp 
Heterozygote = 199 bp and 129 bp 
Wild type = 199 bp 
 
Primers 
K3: TGGAACCCTGTGCCATCTCTAT 
K5-199: 
AGATTGACTATTCATATGCTCTAA 
N1-129: 
TTGCCAAGTTCTAATTCCATCA 
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PCR Conditions Rb1-G 
 
Master Mix per reaction 
- 0.5 L MgCl2 (50mM) 
- 2 L dNTPs (2mM) 
- 2 L 10X PCR Buffer (200mM Tris 
pH8, 500mM KCl) 
- 1L 20M LoxP-N-F-MC 
- 1L 20M LoxP-N-R-MC 
- 11 L Water 
- 0.5L Taq (5units/µL) 
Total   18L 
 + 2L DNA sample 
 
 
 
Reaction Conditions 
Program - NEWRBPRIMERS 
1. 94C 2:00 
2. 94C 0:45 
3. 55C 0:45 
4. 72C 0:45 
5. Go  to Step #2, 39 times 
6. 72C 5:00 
7. 12C hold 
 
Expected Results:  
 
Mutant = 280 bp 
Heterozygote = 280 bp and 200 bp 
Wild type = 200 bp 
 
Primers 
LOXP-N-F-MC: 
CAAATTCTCTTCCATTTCCC 
LOXP-N-R-MC: 
GAATTACAAGTTCAAGACCTAG 
 
 
 
 
 
 
 
 
 
PCR Conditions UBC Cre ERT2 
 
Master Mix per reaction 
- 0.5 L MgCl2 (50mM) 
- 2 L dNTPs (2mM) 
- 2 L 10X PCR Buffer (200mM Tris 
pH8, 500mM KCl) 
- 0.25L 20M Fwd 
- 0.25L 20M Rev 
- 0.25L 20M Internal Fwd 
- 0.25L 20M Internal Rev 
- 12 L Water 
- 0.5L Taq (5units/µL) 
Total   18L 
 + 2L DNA sample 
 
Reaction Conditions 
Program – SL01 
1. 94C 2:30 
2. 94C 0:20 
3. 60C 0:20 
4. 70C 2:00 
5. Go  to Step #2, 29 times 
6. 72C 10:00 
7. 12C hold 
 
Expected Results:  
 
Positive = 100 bp 
Internal Control = 324 bp 
 
 
Primers 
Fwd: GCG GTC TGG CAG TAA AAA 
CTA TC 
Rev: GTG AAA CAG CAT TGC TGT 
CAC TT  
Internal Fwd: CTA GGC CAC AGA 
ATT GAA AGA TCT 
Internal Rev:  
GTA GGT GGA AAT TCT AGC ATC 
ATC C 
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PCR Conditions p53 
 
Master Mix per reaction 
- 1 L MgCl2 (50mM) 
- 2.5 L dNTPs (2mM) 
- 2.5 L 10X PCR Buffer (200mM Tris 
pH8, 500mM KCl) 
- 0.62L 20M AM3 primer 
- 0.62L 20M AM4 primer 
- 0.27L 20M neo-sense primer 
- 0.27L 20M neo-antisense primer 
- 11 L Water 
- 0.5L Taq (5units/µL) 
Total   18L 
 + 2L DNA sample 
 
Reaction Conditions 
Program – P53 New 
1. 94C 2:30 
2. 94C 0:30 
3. 58C 0:30 
4. 72C 1:10 
5. Go  to Step #2, 29 times 
6. 72C 10:00 
7. 12C hold 
 
Expected Results:  
 
Mutant (Null) = 424 bp 
Heterozygote = 424 bp and 548 bp 
Wild type = 548 bp 
 
 
Primers 
AM3: ATAGGTCGGCGGTTCAT 
AM4: CCCGAGTATCTGGAAGACAG  
Neo-sense: 
GGAAGGGACTGGCTGCTATTG 
Neo-antisense: 
CAATATCACGGGTAGCCAACG 
 
 
 
 
 
 
PCR Conditions Cdkn1a (p21) 
 
Master Mix per reaction 
- 0.5 L MgCl2 (50mM) 
- 2 L dNTPs (2mM) 
- 2 L 10X PCR Buffer (200mM Tris 
pH8, 500mM KCl) 
- 1L 20M N1 
- 1L 20M K3 
- 1L 20M K5 
- 10 L Water 
- 0.5L Taq (5units/µL) 
Total   18L 
 + 2L DNA sample 
 
 
Reaction Conditions 
Program - P21 
1. 94C 2:00 
2. 94C 0:45 
3. 57C 0:45 
4. 72C 0:45 
5. Go  to Step #2, 34 times 
6. 72C 7:00 
7. 12C hold 
 
Expected Results:  
 
Mutant (Null) = 700 bp 
Heterozygote = 872 bp and 700 bp 
Wild type = 872 bp 
 
 
Primers 
Wild-type: TGA CGA AGT CAA AGT 
TCC ACC 
Common: AAG CCT TGA TTC TGA 
TGT GGG C 
Mutant: GCT ATC AGG ACA TAG 
CGT TGG C 
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PCR Conditions KrasG12D 
Master Mix per reaction 
- 0.6 L MgCl2 (50mM) 
- 2 L dNTPs (2mM) 
- 2 L 10X PCR Buffer (200mM Tris pH8, 500mM KCl) 
- 0.5L 20M Primer K1 
- 0.5L 20M Primer K2 
- 0.5L 20M Primer K3 
- 11.4 L Water 
- 0.5L Taq (5units/µL) 
Total   18L 
 + 2L DNA sample 
 
 
Reaction Conditions 
Program - P21 
1. 95C 2:00 
2. 95C 0:30 
3. 61C 0:30 
4. 72C 0:45 
5. Go  to Step #2, 34 times 
6. 72C 10:00 
7. 4C hold 
 
Expected Results:  
 
Wild type = 622 bp 
LSL cassette = 500 bp 
1 Lox (Recombined after Cre = 650 bp 
 
Primers 
Wild-type: TGA CGA AGT CAA AGT TCC ACC 
Common: AAG CCT TGA TTC TGA TGT GGG C 
Mutant: GCT ATC AGG ACA TAG CGT TGG C 
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Appendix E: Permission for publication by Molecular and 
Cellular Biology 
Data presented in chapter 2 is published in the journal of Molecular and Cellular Biology 
Thwaites, M. J., Cecchini, M. J., Passos, D. T., Welch, I. & Dick, F. A. Interchangeable 
Roles for E2F Transcriptional Repression by the Retinoblastoma Protein and p27KIP1-
Cyclin-Dependent Kinase Regulation in Cell Cycle Control and Tumor Suppression. Mol 
Cell Biol 37, doi:10.1128/MCB.00561-16 (2017). 
 
Data presented in appendix is published in the journal of Molecular and Cellular Biology 
Cecchini, M.J., Thwaites, M.J., Talluri, S., MacDonald, J.I., Passos, D.T., Chong, J.L., 
Cantalupo, P., Stafford, P.M., Saenz-Robles, M.T., Francis, S.M., et al. A retinoblastoma 
allele that is mutated at its common E2F interaction site inhibits cell proliferation in gene-
targeted mice. Mol Cell Biol 34, 2029-2045, doi:10.1128/MCB.01589-13 (2014). 
 
See following page for the permission from Molecular and Cellular Biology 
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